ICK
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O00458 | S15 | Sugiyama | IFRD1 | ______MPKNKKRNtPHRGssAGGGGsGAAAATAATAGGQH |
| O00488 | S93 | Sugiyama | ZNF593 ZT86 | STNLKTHFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVP |
| O14908 | S232 | Sugiyama | GIPC1 C19orf3 GIPC RGS19IP1 | TEPRKAFDMISQRsAGGRPGsGPQLGtGRGtLRLRsRGPAt |
| O43143 | S656 | Sugiyama | DHX15 DBP1 DDX15 | QNHESVQWCYDNFINYRSLMsADNVRQQLSRIMDRFNLPRR |
| O43852 | S44 | Sugiyama | CALU | KKDRVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQL |
| O60573 | S74 | Sugiyama | EIF4E2 EIF4EL3 | HPLQYNYTFWYSRRtPGRPtsSQSyEQNIKQIGTFASVEQF |
| O60716 | S252 | Sugiyama | CTNND1 KIAA0384 | sRVtRIEERyRPsMEGyRAPsRQDVyGPQPQVRVGGssVDL |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| O75122 | S22 | Sugiyama | CLASP2 KIAA0627 | AMGDDKsFDDEEsVDGNRPssAAsAFKVPAPKTSGNPANSA |
| O75821 | S189 | Sugiyama | EIF3G EIF3S4 | CPYKDtLGPMQKELAEQLGLstGEKEKLPGELEPVQAtQNK |
| O75822 | T33 | Sugiyama | EIF3J EIF3S1 PRO0391 | sWDADAFsVEDPVRKVGGGGtAGGDRWEGEDEDEDVKDNWD |
| O95218 | S65 | Sugiyama | ZRANB2 ZIS ZNF265 | MKAGGtEIGKtLAEKSRGLFsANDWQCKTCsNVNWARRsEC |
| P00966 | T219 | Sugiyama | ASS1 ASS | KNQAPPGLytKtQDPAKAPNtPDILEIEFKKGVPVKVTNVK |
| P04040 | T28 | Sugiyama | CAT | ASDQMQHWKEQRAAQKADVLttGAGNPVGDKLNVItVGPRG |
| P04040 | T434 | Sugiyama | CAT | QQPSALEHSIQYSGEVRRFNtANDDNVtQVRAFyVNVLNEE |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04181 | T39 | Sugiyama | OAT | HSSVASATSVATKKtVQGPPtSDDIFEREyKyGAHNyHPLP |
| P04406 | T211 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | PsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtGM |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P04792 | T174 | Sugiyama | HSPB1 HSP27 HSP28 | SSsLsPEGtLTVEAPMPKLAtQsNEItIPVtFEsRAQLGGP |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05783 | S30 | Sugiyama | KRT18 CYK18 PIG46 | stNyRsLGsVQAPsyGARPVssAAsVyAGAGGsGsRIsVsR |
| P05783 | S31 | Sugiyama | KRT18 CYK18 PIG46 | tNyRsLGsVQAPsyGARPVssAAsVyAGAGGsGsRIsVsRs |
| P06493 | T47 | Sugiyama | CDK1 CDC2 CDC28A CDKN1 P34CDC2 | GQVVAMKKIRLEsEEEGVPstAIREIsLLKELRHPNIVSLQ |
| P07195 | T302 | Sugiyama | LDHB | YGIENEVFLSLPCILNARGLtsVINQKLKDDEVAQLKKsAD |
| P07437 | S172 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | ISKIREEYPDRIMNtFsVVPsPKVSDTVVEPYNATLSVHQL |
| P07437 | S75 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tGGKyVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| P07437 | T166 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | GMGTLLISKIREEYPDRIMNtFsVVPsPKVSDTVVEPYNAT |
| P08174 | S106 | Sugiyama | CD55 CR DAF | QWSDIEEFCNRSCEVPtRLNsAsLKQPYITQNyFPVGtVVE |
| P08195 | S607 | Sugiyama | SLC3A2 MDU1 | ASLPAKADLLLstQPGREEGsPLELERLKLEPHEGLLLRFP |
| P08238 | S460 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQ |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08865 | T97 | Sugiyama | RPSA LAMBR LAMR1 | IssRNtGQRAVLKFAAAtGAtPIAGRFtPGTFTNQIQAAFR |
| P0DPH7 | S48 | Sugiyama | TUBA3C TUBA2 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P0DPH7 | T56 | Sugiyama | TUBA3C TUBA2 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVVD |
| P10809 | S70 | Sugiyama | HSPD1 HSP60 | AVAVTMGPKGRtVIIEQsWGsPKVTKDGVtVAKsIDLKDKY |
| P11142 | T222 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | GGTFDVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVNHFI |
| P11142 | T38 | Sugiyama | HSPA8 HSC70 HSP73 HSPA10 | VGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQ |
| P11586 | T148 | Sugiyama | MTHFD1 MTHFC MTHFD | tsINAGKLARGDLNDCFIPCtPKGCLELIKETGVPIAGRHA |
| P12270 | S648 | Sugiyama | TPR | LHAssLDDVsLAstPKRPstsQtVstPAPVPVIESTEAIEA |
| P12270 | T650 | Sugiyama | TPR | AssLDDVsLAstPKRPstsQtVstPAPVPVIESTEAIEAKA |
| P13639 | S593 | Sugiyama | EEF2 EF2 | SDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGL |
| P13639 | T5 | Sugiyama | EEF2 EF2 | ________________MVNFtVDQIRAIMDKKANIRNMsVI |
| P13639 | T735 | Sugiyama | EEF2 EF2 | HRGGGQIIPtARRCLyAsVLtAQPRLMEPIyLVEIQCPEQV |
| P13929 | S14 | Sugiyama | ENO3 | _______MAMQKIFAREILDsRGNPtVEVDLHtAKGRFRAA |
| P13929 | T26 | Sugiyama | ENO3 | IFAREILDsRGNPtVEVDLHtAKGRFRAAVPsGAstGIyEA |
| P14618 | S205 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | VKQKGADFLVtEVENGGsLGsKKGVNLPGAAVDLPAVsEKD |
| P14618 | S37 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | QLHAAMADTFLEHMCRLDIDsPPItARNtGIICtIGPAsRs |
| P14618 | S55 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | IDsPPItARNtGIICtIGPAsRsVEtLKEMIKsGMNVARLN |
| P14618 | T121 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | DPILyRPVAVALDTKGPEIRtGLIKGsGtAEVELKKGATLK |
| P14618 | T41 | Sugiyama | PKM OIP3 PK2 PK3 PKM2 | AMADTFLEHMCRLDIDsPPItARNtGIICtIGPAsRsVEtL |
| P14625 | S64 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | tDDEVVQREEEAIQLDGLNAsQIRELREKSEKFAFQAEVNR |
| P14625 | T171 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | GVGMtREELVKNLGTIAKsGtsEFLNKMTEAQEDGQSTSEL |
| P15924 | S2825 | Sugiyama | DSP | AAsVssKGLPsPyNMssAPGsRsGsRsGsRSGsRsGsRsGs |
| P17066 | T40 | Sugiyama | HSPA6 HSP70B' | VGVFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQ |
| P18615 | S115 | Sugiyama | NELFE RD RDBP | KLKDPEKGPVPTFQPFQRsIsADDDLQEsSRRPQRKsLyEs |
| P19338 | S580 | Sugiyama | NCL | PRGsPNARSQPSKTLFVKGLsEDttEEtLKEsFDGsVRARI |
| P19525 | T529 | Sugiyama | EIF2AK2 PKR PRKR | KKEKTLLQKLLSKKPEDRPNtSEILRTLTVWKKsPEKNERH |
| P20794 | T218 | Sugiyama | MAK | PLFPGTSEVDEIFKICQVLGtPKKSDWPEGYQLASSMNFRF |
| P21333 | S2319 | Sugiyama | FLNA FLN FLN1 | VQEPGDyEVsVKFNEEHIPDsPFVVPVAsPsGDARRLtVss |
| P21333 | S2327 | Sugiyama | FLNA FLN FLN1 | VsVKFNEEHIPDsPFVVPVAsPsGDARRLtVssLQEsGLKV |
| P22234 | S27 | Sugiyama | PAICS ADE2 AIRC PAIS | LNIGKKLYEGKtKEVyELLDsPGKVLLQsKDQItAGNAARK |
| P22626 | S212 | Sugiyama | HNRNPA2B1 HNRPA2B1 | EMQEVQssRsGRGGNFGFGDsRGGGGNFGPGPGsNFRGGsD |
| P23246 | T687 | Sugiyama | SFPQ PSF | FGQGGAGPVGGQGPRGMGPGtPAGyGRGREEYEGPNKKPRF |
| P23284 | T81 | Sugiyama | PPIB CYPB | IFGLFGKTVPKTVDNFVALAtGEKGFGYKNSKFHRVIKDFM |
| P23396 | T242 | Sugiyama | RPS3 OK/SW-cl.26 | PIsEQKGGKPEPPAMPQPVPtA___________________ |
| P23588 | S597 | Sugiyama | EIF4B | KKPEENPASKFssASKyAALsVDGEDENEGEDyAE______ |
| P23921 | S780 | Sugiyama | RRM1 RR1 | KEKVSKEEEEKERNtAAMVCsLENRDECLMCGS________ |
| P23921 | T774 | Sugiyama | RRM1 RR1 | KEKLKDKEKVSKEEEEKERNtAAMVCsLENRDECLMCGS__ |
| P25786 | S14 | Sugiyama | PSMA1 HC2 NU PROS30 PSC2 | _______MFRNQyDNDVtVWsPQGRIHQIEYAMEAVKQGSA |
| P27540 | T227 | Sugiyama | ARNT BHLHE2 | STLYDQVHPDDVDKLREQLStSENALTGRILDLKTGTVKKE |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P27797 | S53 | Sugiyama | CALR CRTC | WtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDAR |
| P27824 | S362 | Sugiyama | CANX | WDEDMDGEWEAPQIANPRCEsAPGCGVWQRPVIDNPNyKGK |
| P28066 | S16 | Sugiyama | PSMA5 | _____MFLTRsEyDRGVNtFsPEGRLFQVEyAIEAIKLGST |
| P28066 | S172 | Sugiyama | PSMA5 | QLFHMDPsGtFVQCDARAIGsAsEGAQssLQEVyHKSMTLK |
| P29401 | T442 | Sugiyama | TKT | GEDGPSQMALEDLAMFRsVPtstVFyPsDGVAtEKAVELAA |
| P29692 | S119 | Sugiyama | EEF1D EF1D | QELQQAIsKLEARLNVLEKssPGHRAtAPQtQHVsPMRQVE |
| P29692 | S65 | Sugiyama | EEF1D EF1D | VILRDIARARENIQKsLAGssGPGAssGtsGDHGELVVRIA |
| P29692 | T125 | Sugiyama | EEF1D EF1D | IsKLEARLNVLEKssPGHRAtAPQtQHVsPMRQVEPPAKKP |
| P29692 | T129 | Sugiyama | EEF1D EF1D | EARLNVLEKssPGHRAtAPQtQHVsPMRQVEPPAKKPAtPA |
| P30041 | T48 | Sugiyama | PRDX6 AOP2 KIAA0106 | FLGDSWGILFSHPRDFtPVCttELGRAAKLAPEFAKRNVKL |
| P31943 | S104 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | EVFKSNNVEMDWVLKHtGPNsPDtANDGFVRLRGLPFGCSK |
| P33176 | S175 | Sugiyama | KIF5B KNS KNS1 | VHEDKNRVPYVKGCTERFVCsPDEVMDtIDEGKSNRHVAVT |
| P33316 | S164 | Sugiyama | DUT | YTIPPMEKAVVKTDIQIALPsGCyGRVAPRSGLAAKHFIDV |
| P34931 | T40 | Sugiyama | HSPA1L | VGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQ |
| P35998 | T193 | Sugiyama | PSMC2 MSS1 | TYSDVGGCKEQIEKLREVVEtPLLHPERFVNLGIEPPKGVL |
| P37802 | S185 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL______ |
| P37802 | T180 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | RNFsDNQLQEGKNVIGLQMGtNRGAsQAGMtGyGMPRQIL_ |
| P37802 | T190 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | GKNVIGLQMGtNRGAsQAGMtGyGMPRQIL___________ |
| P37802 | Y192 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | NVIGLQMGtNRGAsQAGMtGyGMPRQIL_____________ |
| P38646 | S549 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | IVHVSAKDKGTGREQQIVIQssGGLsKDDIENMVKNAEKYA |
| P38646 | T86 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | CVAVMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAK |
| P38646 | T87 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | VAVMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAKR |
| P38646 | T94 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | QAKVLENAEGARttPsVVAFtADGERLVGMPAKRQAVtNPN |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P41091 | T109 | Sugiyama | EIF2S3 EIF2G | YKLDDPSCPRPECyRSCGsstPDEFPtDIPGtKGNFKLVRH |
| P42166 | S159 | Sugiyama | TMPO LAP2 | RKLYEKKLLKLREQGtEsRsstPLPtIsssAENtRQNGsND |
| P42167 | S159 | Sugiyama | TMPO LAP2 | RKLYEKKLLKLREQGTESRsstPLPTISsSAENTRQNGSND |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46013 | S299 | Sugiyama | MKI67 | GLQGETQLLVSRKSRPKsGGsGHAVAEPAsPEQELDQNKGK |
| P46379 | T1080 | EPSD|PSP | BAG6 BAT3 G3 | QLLLSEAVSRAAKAAGARPLtsPEsLsRDLEAPEVQESYRQ |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P48444 | S252 | Sugiyama | ARCN1 COPD | GKEVDNFVDKLKsEGEtIMSssMGKRTSEATKMHAPPINME |
| P48741 | T40 | Sugiyama | HSPA7 HSP70B | VGVFQQGRVEILANDQGNRTtPsyVAFtDtERLVGDAAKsQ |
| P50502 | S181 | Sugiyama | ST13 AAG2 FAM10A1 HIP SNC6 | LQKPNAAIRDCDRAIEINPDsAQPyKWRGKAHRLLGHWEEA |
| P54652 | T225 | Sugiyama | HSPA2 | GGTFDVSILTIEDGIFEVKstAGDtHLGGEDFDNRMVSHLA |
| P54652 | T39 | Sugiyama | HSPA2 | VGVFQHGKVEIIANDQGNRttPsyVAFtDtERLIGDAAKNQ |
| P55072 | S765 | Sugiyama | VCP HEL-220 HEL-S-70 | RsVsDNDIRKyEMFAQtLQQsRGFGsFRFPsGNQGGAGPsQ |
| P55795 | S104 | Sugiyama | HNRNPH2 FTP3 HNRPH2 | EVFKSNsVEMDWVLKHtGPNsPDtANDGFVRLRGLPFGCSK |
| P57721 | T159 | Sugiyama | PCBP3 PCBP3-OT1 PCBP3OT | sQCGsLIGKGGSKIKEIREstGAQVQVAGDMLPNstERAVT |
| P57721 | T174 | Sugiyama | PCBP3 PCBP3-OT1 PCBP3OT | EIREstGAQVQVAGDMLPNstERAVTISGTPDAIIQCVKQI |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60709 | T202 | Sugiyama | ACTB | GRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVALD |
| P61313 | S100 | Sugiyama | RPL15 EC45 TCBAP0781 | tyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLNsyW |
| P61978 | S81 | Sugiyama | HNRNPK HNRPK | GGKNIKALRtDyNAsVsVPDssGPERILsISADIETIGEIL |
| P62241 | S4 | Sugiyama | RPS8 OK/SW-cl.83 | _________________MGIsRDNWHKRRKTGGKRKPYHKK |
| P62263 | S137 | Sugiyama | RPS14 PRO2640 | RALARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL______ |
| P62263 | T105 | Sugiyama | RPS14 PRO2640 | CKELGITALHIKLRATGGNRtKtPGPGAQsALRALARSGMK |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62750 | T42 | Sugiyama | RPL23A | LKAKKAVLKGVHSHKKKKIRtsPTFRRPKTLRLRRQPKYPR |
| P62826 | T66 | Sugiyama | RAN ARA24 OK/SW-cl.81 | EVHPLVFHTNRGPIKFNVWDtAGQEKFGGLRDGYYIQAQCA |
| P62937 | T32 | Sugiyama | PPIA CYPA | VDGEPLGRVsFELFADKVPKtAENFRALSTGEKGFGYKGsC |
| P62942 | S9 | Sugiyama | FKBP1A FKBP1 FKBP12 | ____________MGVQVEtIsPGDGRtFPKRGQtCVVHytG |
| P63173 | T14 | Sugiyama | RPL38 | _______MPRKIEEIKDFLLtARRKDAKSVKIKKNKDNVKF |
| P63261 | T202 | Sugiyama | ACTG1 ACTG | GRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVALD |
| P68363 | S48 | Sugiyama | TUBA1B | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| P68363 | T56 | Sugiyama | TUBA1B | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| P68363 | T73 | Sugiyama | TUBA1B | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| P68363 | T82 | Sugiyama | TUBA1B | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| P68363 | Y83 | Sugiyama | TUBA1B | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| P78347 | S210 | Sugiyama | GTF2I BAP135 WBSCR6 | EPKKHVGGRVMVtDADRsILsPGGsCGPIKVKTEPTEDSGI |
| P78371 | S143 | Sugiyama | CCT2 99D8.1 CCTB | PQTIIAGWREATKAAREALLssAVDHGsDEVKFRQDLMNIA |
| P78371 | S150 | Sugiyama | CCT2 99D8.1 CCTB | WREATKAAREALLssAVDHGsDEVKFRQDLMNIAGTTLssK |
| P78527 | T2645 | Sugiyama | PRKDC HYRC HYRC1 | LSARWPVAGQIRAtQQQHDFtLtQtADGRssFDWLTGsstD |
| P84098 | S37 | Sugiyama | RPL19 | CGKKKVWLDPNEtNEIANANsRQQIRKLIKDGLIIRKPVtV |
| Q00613 | S363 | Sugiyama | HSF1 HSTF1 | AsVTALtDARGHTDtEGRPPsPPPtstPEKCLsVACLDKNE |
| Q00613 | T367 | Sugiyama | HSF1 HSTF1 | ALtDARGHTDtEGRPPsPPPtstPEKCLsVACLDKNELSDH |
| Q01518 | S295 | Sugiyama | CAP1 CAP | SDDMKTHKNPALKAQSGPVRsGPKPFsAPKPQtsPsPKRAT |
| Q01518 | S301 | Sugiyama | CAP1 CAP | HKNPALKAQSGPVRsGPKPFsAPKPQtsPsPKRATKKEPAV |
| Q01518 | S310 | Sugiyama | CAP1 CAP | SGPVRsGPKPFsAPKPQtsPsPKRATKKEPAVLELEGKKWR |
| Q01518 | T307 | Sugiyama | CAP1 CAP | KAQSGPVRsGPKPFsAPKPQtsPsPKRATKKEPAVLELEGK |
| Q01581 | T506 | Sugiyama | HMGCS1 HMGCS | sNIAtEHIPsPAKKVPRLPAtAAEPEAAVIsNGEH______ |
| Q02543 | T102 | Sugiyama | RPL18A | LRYDsRSGtHNMYREyRDLttAGAVtQCyRDMGARHRARAH |
| Q02543 | T24 | Sugiyama | RPL18A | SGTLREYKVVGRCLPTPKCHtPPLYRMRIFAPNHVVAKSRF |
| Q02543 | Y97 | Sugiyama | RPL18A | NFGIWLRYDsRSGtHNMYREyRDLttAGAVtQCyRDMGARH |
| Q10713 | T294 | Sugiyama | PMPCA INPP5E KIAA0123 MPPA | VQPAWGSAEAVDIDRSVAQytGGIAKLERDMSNVSLGPTPI |
| Q12789 | S848 | Sugiyama | GTF3C1 | ERRTIKQESGRAGVRPsssGsAWEACSEAPSKGSQDGVTWE |
| Q13263 | T415 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | LNAWTKSAEAFGKIVAERPGtNstGPAPMAPPRAPGPLSKQ |
| Q13283 | S232 | Sugiyama | G3BP1 G3BP | EEKPEPVLEETAPEDAQKsssPAPADIAQtVQEDLRtFsWA |
| Q13509 | S172 | Sugiyama | TUBB3 TUBB4 | ISKVREEYPDRIMNtFsVVPsPKVSDTVVEPYNATLSIHQL |
| Q13509 | S75 | Sugiyama | TUBB3 TUBB4 | SSHKYVPRAILVDLEPGtMDsVRSGAFGHLFRPDNFIFGQS |
| Q13509 | T166 | Sugiyama | TUBB3 TUBB4 | GMGTLLISKVREEYPDRIMNtFsVVPsPKVSDTVVEPYNAT |
| Q13561 | S202 | Sugiyama | DCTN2 DCTN50 | EATKNSKGGSGGKttGtPPDssLVtyELHsRPEQDKFSQAA |
| Q13884 | S87 | Sugiyama | SNTB1 SNT2B1 | SFCRGAGAGHPGAGGAQPPDsPAGVRTAFTDLPEQVPESIS |
| Q13885 | S75 | Sugiyama | TUBB2A TUBB2 | AGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q14103 | T193 | Sugiyama | HNRNPD AUF1 HNRPD | KAMKTKEPVKKIFVGGLsPDtPEEKIREYFGGFGEVESIEL |
| Q14181 | T130 | Sugiyama | POLA2 | LNSYttPSKGSQKRAIstPEtPLtKRsVstRsPHQLLsPss |
| Q14181 | T133 | Sugiyama | POLA2 | YttPSKGSQKRAIstPEtPLtKRsVstRsPHQLLsPssFsP |
| Q14204 | S3082 | Sugiyama | DYNC1H1 DHC1 DNCH1 DNCL DNECL DYHC KIAA0325 | LHVVFTMNPSSEGLKDRAAtsPALFNRCVLNWFGDWSTEAL |
| Q14657 | T29 | Sugiyama | LAGE3 DXS9879E ESO3 ITBA2 | GGGADGGDGRGGHSCRGGVDtAAAPAGGAPPAHAPGPGRDA |
| Q14980 | S1862 | Sugiyama | NUMA1 NMP22 NUMA | PAsQAsLRAtsstQsLARLGsPDYGNsALLsLPGyRPttRs |
| Q15293 | T76 | Sugiyama | RCN1 RCN | FQYDHEAFLGKEDsKtFDQLtPDEsKERLGKIVDRIDNDGD |
| Q15365 | T127 | Sugiyama | PCBP1 | TQCGsLIGKGGCKIKEIREstGAQVQVAGDMLPNstERAIT |
| Q15365 | T142 | Sugiyama | PCBP1 | EIREstGAQVQVAGDMLPNstERAITIAGVPQSVTECVKQI |
| Q15366 | T127 | Sugiyama | PCBP2 | sQCGsLIGKGGCKIKEIREstGAQVQVAGDMLPNstERAIT |
| Q15366 | T142 | Sugiyama | PCBP2 | EIREstGAQVQVAGDMLPNstERAITIAGIPQSIIECVKQI |
| Q15642 | T302 | Sugiyama | TRIP10 CIP4 STOT STP | VEFEDFsQPMNRAPsDssLGtPsDGRPELRGPGRSRTKRWP |
| Q16204 | S244 | Sugiyama | CCDC6 D10S170 TST1 | LEAEKRILQEKLDQPVsAPPsPRDIsMEIDsPENMMRHIRF |
| Q16543 | T370 | Sugiyama | CDC37 CDC37A | EAKEGEEAGPGDPLLEAVPKtGDEKDVsV____________ |
| Q16630 | T157 | Sugiyama | CPSF6 CFIM68 | SKKLMDLLPKRELHGQNPVVtPCNKQFLsQFEMQSRKTTQS |
| Q16637 | S31 | Sugiyama | SMN1 SMN SMNT; SMN2 SMNC | GVPEQEDsVLFRRGtGQsDDsDIWDDtALIKAYDKAVAsFK |
| Q53EL6 | S94 | Sugiyama | PDCD4 H731 | GDsVsDsGsDALRSGLtVPtsPKGRLLDRRSRSGKGRGLPK |
| Q6PEY2 | S48 | Sugiyama | TUBA3E | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q6PEY2 | T56 | Sugiyama | TUBA3E | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVVD |
| Q6PKG0 | S774 | Sugiyama | LARP1 KIAA0731 LARP | LFGAPEPstIARsLPttVPEsPNyRNtRtPRtPRtPQLKDS |
| Q71RC2 | S597 | Sugiyama | LARP4 PP13296 | QttIPVsPPsttKPsRAstAsPCNNNINAAtAVALQEPRKL |
| Q71U36 | S48 | Sugiyama | TUBA1A TUBA3 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q71U36 | T56 | Sugiyama | TUBA1A TUBA3 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| Q71U36 | T73 | Sugiyama | TUBA1A TUBA3 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q71U36 | T82 | Sugiyama | TUBA1A TUBA3 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q71U36 | Y83 | Sugiyama | TUBA1A TUBA3 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q7Z2W4 | T273 | Sugiyama | ZC3HAV1 ZC3HDC2 PRO1677 | FFQGsQEFLASASAsAERsCtPsPDQIsHRAsLEDAPVDDL |
| Q86V81 | S239 | Sugiyama | ALYREF ALY BEF THOC4 | tRGGARGRGRGAGRNSKQQLsAEELDAQLDAyNARMDts__ |
| Q86V81 | T148 | Sugiyama | ALYREF ALY BEF THOC4 | EFGtLKKAAVHYDRsGRsLGtADVHFERKADALKAMKQYNG |
| Q86X29 | S510 | Sugiyama | LSR ILDR3 LISCH | RARsVDALDDLtPPstAEsGsRsPtsNGGRSRAYMPPRsRs |
| Q86X29 | T514 | Sugiyama | LSR ILDR3 LISCH | VDALDDLtPPstAEsGsRsPtsNGGRSRAYMPPRsRsRDDL |
| Q8IWS0 | S346 | Sugiyama | PHF6 CENP-31 KIAA1823 | CKNHSGNDERDEEDEERESKsRGKVEIDQQQLtQQQLNGN_ |
| Q8IWX8 | S822 | Sugiyama | CHERP DAN26 SCAF6 | SKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDSRLGEE |
| Q8IWX8 | T819 | Sugiyama | CHERP DAN26 SCAF6 | RSRSKSYSPGRRRRsRsRsPtPPssAGLGsNsAPPIPDSRL |
| Q8N122 | T908 | SIGNOR|EPSD|PSP | RPTOR KIAA1303 RAPTOR | LtNDVAKQPVSRDLPSGRPGtTGPAGAQYtPHSHQFPRTRK |
| Q8N1G4 | T27 | Sugiyama | LRRC47 KIAA1185 | SESWPELELAERERRRELLLtGPGLEERVRAAGGQLPPRLF |
| Q8N684 | T203 | Sugiyama | CPSF7 | GGIPPRAHsRDssDsADGRAtPsENLVPSSARVDKPPSVLP |
| Q8NBJ5 | S612 | Sugiyama | COLGALT1 GLT25D1 PSEC0241 | QKMREQQALSREAKNsDVLQsPLDsAARDEL__________ |
| Q8NBJ5 | S616 | Sugiyama | COLGALT1 GLT25D1 PSEC0241 | EQQALSREAKNsDVLQsPLDsAARDEL______________ |
| Q8NBJ7 | T260 | Sugiyama | SUMF2 PSEC0171 UNQ1968/PRO4500 | SPYQAAEQDMRVLRGAsWIDtADGsANHRARVttRMGNtPD |
| Q8NBJ7 | T278 | Sugiyama | SUMF2 PSEC0171 UNQ1968/PRO4500 | IDtADGsANHRARVttRMGNtPDsAsDNLGFRCAADAGRPP |
| Q8NFI4 | S181 | Sugiyama | ST13P5 FAM10A5 | LQKPNAAIQDCDRAIEINPDsAQPyKWRGKAHRLLGHWEEA |
| Q8WUF5 | S120 | Sugiyama | PPP1R13L IASPP NKIP1 PPP1R13BL RAI | sEsAPtLHPysPLsPKGRPssPRtPLyLQPDAyGsLDRATS |
| Q8WUF5 | T123 | Sugiyama | PPP1R13L IASPP NKIP1 PPP1R13BL RAI | APtLHPysPLsPKGRPssPRtPLyLQPDAyGsLDRATSPRP |
| Q8WWM7 | S111 | Sugiyama | ATXN2L A2D A2LG A2LP A2RP | PGAAAIGsARGQstGKGPPQsPVFEGVyNNSRMLHFLTAVV |
| Q969X0 | T197 | Sugiyama | RILPL2 RLP2 | REKDAVVTSAKNAGRNKEEKtIIKKLFFFRSGKQT______ |
| Q96B36 | S212 | Sugiyama | AKT1S1 PRAS40 | GFKEKRtEARssDEENGPPssPDLDRIAAsMRALVLREAED |
| Q96C19 | S74 | Sugiyama | EFHD2 SWS1 | ELSAKLLRRADLNQGIGEPQsPsRRVFNPytEFKEFSRKQI |
| Q96CV9 | T525 | Sugiyama | OPTN FIP2 GLC1E HIP7 HYPL NRP | AFEDGGRQsLMEMQsRHGARtsDsDQQAyLVQRGAEDRDWR |
| Q96EP5 | S204 | Sugiyama | DAZAP1 | EVKRAEPRDsKsQAPGQPGAsQWGsRVVPNAANGWAGQPPP |
| Q96MH2 | S76 | Sugiyama | HEXIM2 L3 | EDLAGAVGGLGWNsRsPRtQsPGGCsAEAVLARKKHRRRPS |
| Q96QR8 | S23 | Sugiyama | PURB | DGDsGsERGGGGGPCGFQPAsRGGGEQEtQELASKRLDIQN |
| Q96S55 | T116 | Sugiyama | WRNIP1 WHIP | GEEGDDGGETESREsyDAPPtPsGARLIPDFPVARsssPGR |
| Q9BQ04 | T152 | Sugiyama | RBM4B RBM30 | DNTEFQGKRMHVQLSTSRLRtAPGMGDQSGCYRCGKEGHWS |
| Q9BQE3 | S48 | Sugiyama | TUBA1C TUBA6 | HGIQPDGQMPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFV |
| Q9BQE3 | T56 | Sugiyama | TUBA1C TUBA6 | MPSDKtIGGGDDsFNtFFsEtGAGKHVPRAVFVDLEPtVID |
| Q9BQE3 | T73 | Sugiyama | TUBA1C TUBA6 | FsEtGAGKHVPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLI |
| Q9BQE3 | T82 | Sugiyama | TUBA1C TUBA6 | VPRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANN |
| Q9BQE3 | Y83 | Sugiyama | TUBA1C TUBA6 | PRAVFVDLEPtVIDEVRtGtyRQLFHPEQLItGKEDAANNy |
| Q9BQG0 | S11 | Sugiyama | MYBBP1A P160 | __________MEsRDPAQPMsPGEAtQsGARPADRYGLLKH |
| Q9BV73 | S2229 | Sugiyama | CEP250 CEP2 CNAP1 | QRLQDELELTRRALEKERLHsPGAtsTAELGSRGEQGVQLG |
| Q9BVA1 | S75 | Sugiyama | TUBB2B | tGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q9BWF3 | T152 | Sugiyama | RBM4 RBM4A | DNTEFQGKRMHVQLSTSRLRtAPGMGDQSGCYRCGKEGHWS |
| Q9C0C2 | S1103 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | KRGWVGEFSLSVGPQREAAFsPGQQDWsRDFCIEASERsyQ |
| Q9C0C2 | S983 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | sGGsSRtLDAQDRsFGtRPLssGFsPEEAQQQDEEFEKKIP |
| Q9NVU7 | T552 | Sugiyama | SDAD1 NUC130 | SMPMEERKAKAAAISTSRVLtQEDFQKIRMAQMRKELDAAP |
| Q9NWB6 | S77 | Sugiyama | ARGLU1 | RsRstNTAVSRRERDRERAssPPDRIDIFGRTVSKRSSLDE |
| Q9NYB0 | S203 | Sugiyama | TERF2IP DRIP5 RAP1 PP8000 | RYLKHLRGQEHKyLLGDAPVsPssQKLKRKAEEDPEAADsG |
| Q9UI15 | S185 | Sugiyama | TAGLN3 NP25 | EQLRQGQNVIGLQMGSNKGAsQAGMtGyGMPRQIM______ |
| Q9UI15 | T190 | Sugiyama | TAGLN3 NP25 | GQNVIGLQMGSNKGAsQAGMtGyGMPRQIM___________ |
| Q9UI15 | Y192 | Sugiyama | TAGLN3 NP25 | NVIGLQMGSNKGAsQAGMtGyGMPRQIM_____________ |
| Q9UNF1 | T81 | Sugiyama | MAGED2 BCG1 | SGVSKAtEVsKtPEAREAPAtQAssttQLtDtQVLAAENKS |
| Q9UPZ9 | Y159 | SIGNOR|ELM|EPSD | CILK1 ICK KIAA0936 | VKIADFGLAREIRSKPPYtDyVsTRWYRAPEVLLRSTNYSS |
| Q9UQ35 | S2132 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | SRMsCFsRPsMsPtPLDRCRsPGMLEPLGssRtPMsVLQQA |
| Q9Y262 | T248 | Sugiyama | EIF3L EIF3EIP EIF3S6IP HSPC021 HSPC025 MSTP005 | LNVLHSLVDKSNINRQLEVytsGGDPEsVAGEyGRHSLYKM |
| Q9Y266 | S139 | Sugiyama | NUDC | IDQKKDAENHEAQLKNGsLDsPGKQDtEEDEEEDEKDKGKL |
| Q9Y496 | T672 | PSP | KIF3A KIF3 | YLAYTEESLRQSLMKLERPRtSKGKARPKTGRRKRsAKPEt |
| Q9Y6G9 | S207 | Sugiyama | DYNC1LI1 DNCLI1 | EQKLIRDFQEyVEPGEDFPAsPQRRNtAsQEDKDDsVVLPL |
| Q9Y6G9 | T389 | Sugiyama | DYNC1LI1 DNCLI1 | AEDDQVFLMKLQsLLAKQPPtAAGRPVDAsPRVPGGsPRtP |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Chromatin organization | R-HSA-4839726 | 3.570869e-08 | 7.447 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.197551e-07 | 6.922 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 2.696243e-07 | 6.569 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.948875e-06 | 5.530 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 5.225756e-06 | 5.282 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 5.162916e-06 | 5.287 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 6.287392e-06 | 5.202 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 1.629746e-05 | 4.788 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.589398e-05 | 4.587 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.105383e-05 | 4.387 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.114440e-05 | 4.148 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 1.016186e-04 | 3.993 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.029226e-04 | 3.987 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.397856e-04 | 3.855 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.425989e-04 | 3.846 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.148870e-04 | 3.668 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.202809e-04 | 3.657 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 3.122389e-04 | 3.506 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.170842e-04 | 3.499 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 3.136888e-04 | 3.504 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 2.979654e-04 | 3.526 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.827400e-04 | 3.549 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.748505e-04 | 3.561 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 3.747780e-04 | 3.426 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.913431e-04 | 3.407 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.685117e-04 | 3.329 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.047782e-04 | 3.297 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 6.688564e-04 | 3.175 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 6.688564e-04 | 3.175 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 7.840786e-04 | 3.106 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 9.297607e-04 | 3.032 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.150660e-03 | 2.939 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.160425e-03 | 2.935 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.199622e-03 | 2.921 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.236009e-03 | 2.908 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.270062e-03 | 2.896 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.370204e-03 | 2.863 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.342070e-03 | 2.872 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.327416e-03 | 2.877 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 1.510108e-03 | 2.821 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.541352e-03 | 2.812 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.541352e-03 | 2.812 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.478577e-03 | 2.830 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 1.615077e-03 | 2.792 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.685902e-03 | 2.773 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.857390e-03 | 2.731 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.179505e-03 | 2.662 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 2.313807e-03 | 2.636 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 2.470071e-03 | 2.607 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.502771e-03 | 2.602 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 2.549763e-03 | 2.594 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.601385e-03 | 2.585 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.859480e-03 | 2.544 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 2.857129e-03 | 2.544 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.994251e-03 | 2.524 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 3.083939e-03 | 2.511 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 3.244405e-03 | 2.489 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 3.380202e-03 | 2.471 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.593990e-03 | 2.444 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 3.487152e-03 | 2.458 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 3.683018e-03 | 2.434 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.270133e-03 | 2.370 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 4.325533e-03 | 2.364 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 5.104961e-03 | 2.292 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 5.050768e-03 | 2.297 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 4.902964e-03 | 2.310 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 5.104961e-03 | 2.292 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 5.163267e-03 | 2.287 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 5.163267e-03 | 2.287 | 0 | 0 |
| M Phase | R-HSA-68886 | 5.678902e-03 | 2.246 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 6.275145e-03 | 2.202 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 6.201867e-03 | 2.207 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 6.251539e-03 | 2.204 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 6.251539e-03 | 2.204 | 0 | 0 |
| S Phase | R-HSA-69242 | 6.465213e-03 | 2.189 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.173663e-03 | 2.209 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 6.275145e-03 | 2.202 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 6.410459e-03 | 2.193 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 6.791897e-03 | 2.168 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 6.861692e-03 | 2.164 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 7.205318e-03 | 2.142 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 7.373275e-03 | 2.132 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 7.373275e-03 | 2.132 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 7.373275e-03 | 2.132 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 7.311011e-03 | 2.136 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 7.373275e-03 | 2.132 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 7.630651e-03 | 2.117 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 8.108185e-03 | 2.091 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 7.789762e-03 | 2.108 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 8.290288e-03 | 2.081 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 8.489808e-03 | 2.071 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 9.186591e-03 | 2.037 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 9.101420e-03 | 2.041 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 9.156404e-03 | 2.038 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 9.250464e-03 | 2.034 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 9.250464e-03 | 2.034 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 9.566287e-03 | 2.019 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 9.611471e-03 | 2.017 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 9.611471e-03 | 2.017 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 9.887429e-03 | 2.005 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.077931e-02 | 1.967 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 1.047546e-02 | 1.980 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.110269e-02 | 1.955 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 1.110269e-02 | 1.955 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.122621e-02 | 1.950 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 1.269072e-02 | 1.897 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 1.269072e-02 | 1.897 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.269072e-02 | 1.897 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.269072e-02 | 1.897 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.234590e-02 | 1.908 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.239096e-02 | 1.907 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 1.323685e-02 | 1.878 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.332539e-02 | 1.875 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 1.369702e-02 | 1.863 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.369702e-02 | 1.863 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.440807e-02 | 1.841 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.428549e-02 | 1.845 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.490127e-02 | 1.827 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.490127e-02 | 1.827 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.565840e-02 | 1.805 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.644034e-02 | 1.784 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 1.735493e-02 | 1.761 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.735493e-02 | 1.761 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.799138e-02 | 1.745 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.841151e-02 | 1.735 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.893372e-02 | 1.723 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.939053e-02 | 1.712 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.002048e-02 | 1.699 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.952333e-02 | 1.709 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.004969e-02 | 1.698 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 2.004969e-02 | 1.698 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.058492e-02 | 1.686 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 2.069022e-02 | 1.684 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.121166e-02 | 1.673 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.140958e-02 | 1.669 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.181532e-02 | 1.661 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 2.209349e-02 | 1.656 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.437822e-02 | 1.613 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.266664e-02 | 1.645 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.245371e-02 | 1.649 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.278126e-02 | 1.642 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 2.485108e-02 | 1.605 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.485108e-02 | 1.605 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.504251e-02 | 1.601 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 2.504603e-02 | 1.601 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 2.508451e-02 | 1.601 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 2.517997e-02 | 1.599 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.530709e-02 | 1.597 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.530709e-02 | 1.597 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 2.813740e-02 | 1.551 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 2.869011e-02 | 1.542 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.615176e-02 | 1.582 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.813740e-02 | 1.551 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.869011e-02 | 1.542 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.759427e-02 | 1.559 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.875082e-02 | 1.541 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 3.197224e-02 | 1.495 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.197224e-02 | 1.495 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 3.415757e-02 | 1.467 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 3.415757e-02 | 1.467 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 3.415757e-02 | 1.467 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.317293e-02 | 1.479 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 3.294483e-02 | 1.482 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.324316e-02 | 1.478 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 3.294984e-02 | 1.482 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 3.088915e-02 | 1.510 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.150575e-02 | 1.502 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.206689e-02 | 1.494 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 3.143605e-02 | 1.503 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.415757e-02 | 1.467 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 3.279550e-02 | 1.484 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.279550e-02 | 1.484 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.434824e-02 | 1.464 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 3.445837e-02 | 1.463 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 3.445837e-02 | 1.463 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 3.445837e-02 | 1.463 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 3.445837e-02 | 1.463 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 3.578945e-02 | 1.446 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 3.578945e-02 | 1.446 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.714349e-02 | 1.430 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.783357e-02 | 1.422 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.784403e-02 | 1.422 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 3.812072e-02 | 1.419 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.831942e-02 | 1.417 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 3.847466e-02 | 1.415 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 3.878847e-02 | 1.411 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 4.348889e-02 | 1.362 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 4.348889e-02 | 1.362 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 4.035696e-02 | 1.394 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 3.878847e-02 | 1.411 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 3.961306e-02 | 1.402 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.460542e-02 | 1.351 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 4.528667e-02 | 1.344 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.541081e-02 | 1.343 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.557885e-02 | 1.341 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 4.577187e-02 | 1.339 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.577187e-02 | 1.339 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.758632e-02 | 1.323 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 4.924293e-02 | 1.308 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 4.966868e-02 | 1.304 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 4.983249e-02 | 1.302 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 5.103129e-02 | 1.292 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 5.241326e-02 | 1.281 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 5.298046e-02 | 1.276 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 5.352329e-02 | 1.271 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.372058e-02 | 1.270 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.372058e-02 | 1.270 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 6.030438e-02 | 1.220 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 6.030438e-02 | 1.220 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 6.161862e-02 | 1.210 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 6.161862e-02 | 1.210 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 6.161862e-02 | 1.210 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.495534e-02 | 1.260 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 6.161862e-02 | 1.210 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 5.524515e-02 | 1.258 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 5.761342e-02 | 1.239 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 5.459528e-02 | 1.263 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.239549e-02 | 1.205 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.263777e-02 | 1.203 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 6.382331e-02 | 1.195 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 6.382331e-02 | 1.195 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 6.509237e-02 | 1.186 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.583582e-02 | 1.182 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 6.752735e-02 | 1.171 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 6.752735e-02 | 1.171 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 6.870388e-02 | 1.163 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 6.973787e-02 | 1.157 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 7.291829e-02 | 1.137 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 7.321920e-02 | 1.135 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 7.321920e-02 | 1.135 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 7.321920e-02 | 1.135 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 7.364281e-02 | 1.133 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 7.364281e-02 | 1.133 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 8.623721e-02 | 1.064 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 8.623721e-02 | 1.064 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 8.623721e-02 | 1.064 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 8.623721e-02 | 1.064 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 8.176446e-02 | 1.087 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 8.176446e-02 | 1.087 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 8.176446e-02 | 1.087 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 7.926955e-02 | 1.101 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.503673e-02 | 1.125 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 8.481949e-02 | 1.072 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 8.623721e-02 | 1.064 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 7.688811e-02 | 1.114 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 8.017349e-02 | 1.096 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 8.017349e-02 | 1.096 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.931405e-02 | 1.101 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 7.881313e-02 | 1.103 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 8.176446e-02 | 1.087 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 8.675374e-02 | 1.062 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.675374e-02 | 1.062 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 9.067543e-02 | 1.043 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 9.067543e-02 | 1.043 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 9.067543e-02 | 1.043 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 9.067543e-02 | 1.043 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 9.067543e-02 | 1.043 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 9.067543e-02 | 1.043 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 9.228092e-02 | 1.035 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 9.228092e-02 | 1.035 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 9.376532e-02 | 1.028 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 9.384920e-02 | 1.028 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 9.459914e-02 | 1.024 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 9.517238e-02 | 1.021 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.185061e-01 | 0.926 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.185061e-01 | 0.926 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.185061e-01 | 0.926 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.185061e-01 | 0.926 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.160346e-01 | 0.935 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 1.160346e-01 | 0.935 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 1.160346e-01 | 0.935 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.037248e-01 | 0.984 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.095515e-01 | 0.960 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 1.095515e-01 | 0.960 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.142649e-01 | 0.942 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.087661e-01 | 0.964 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.128730e-01 | 0.947 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 1.170040e-01 | 0.932 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.069575e-01 | 0.971 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 1.142649e-01 | 0.942 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.148417e-01 | 0.940 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.095515e-01 | 0.960 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 1.100877e-01 | 0.958 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.185061e-01 | 0.926 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.148417e-01 | 0.940 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.053782e-01 | 0.977 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 1.095918e-01 | 0.960 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.001789e-01 | 0.999 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.089709e-01 | 0.963 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.037248e-01 | 0.984 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 1.117857e-01 | 0.952 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 1.130288e-01 | 0.947 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 1.189219e-01 | 0.925 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.194466e-01 | 0.923 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.194466e-01 | 0.923 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 1.202358e-01 | 0.920 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 1.211204e-01 | 0.917 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.211875e-01 | 0.917 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 1.228787e-01 | 0.911 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.233021e-01 | 0.909 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 1.242444e-01 | 0.906 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.242444e-01 | 0.906 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.263148e-01 | 0.899 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 1.267604e-01 | 0.897 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 1.277576e-01 | 0.894 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.277576e-01 | 0.894 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.280633e-01 | 0.893 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.281525e-01 | 0.892 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.295166e-01 | 0.888 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.370776e-01 | 0.863 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.370776e-01 | 0.863 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.370776e-01 | 0.863 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.370776e-01 | 0.863 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.370776e-01 | 0.863 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.370776e-01 | 0.863 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.370776e-01 | 0.863 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.370776e-01 | 0.863 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.553718e-01 | 0.593 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.553718e-01 | 0.593 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI) | R-HSA-9036092 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.553718e-01 | 0.593 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.553718e-01 | 0.593 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 1.687945e-01 | 0.773 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.687945e-01 | 0.773 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 1.687945e-01 | 0.773 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 2.218636e-01 | 0.654 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 2.218636e-01 | 0.654 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 2.218636e-01 | 0.654 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 3.574554e-01 | 0.447 | 0 | 0 |
| Mitochondrial transcription initiation | R-HSA-163282 | 3.574554e-01 | 0.447 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.574554e-01 | 0.447 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.574554e-01 | 0.447 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 3.574554e-01 | 0.447 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 3.574554e-01 | 0.447 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 3.574554e-01 | 0.447 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 3.574554e-01 | 0.447 | 0 | 0 |
| Defective SLC9A9 causes autism 16 (AUTS16) | R-HSA-5619052 | 3.574554e-01 | 0.447 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 3.574554e-01 | 0.447 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 3.574554e-01 | 0.447 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 3.574554e-01 | 0.447 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 3.574554e-01 | 0.447 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 3.574554e-01 | 0.447 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 3.574554e-01 | 0.447 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 3.574554e-01 | 0.447 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 3.574554e-01 | 0.447 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 1.846794e-01 | 0.734 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 1.846794e-01 | 0.734 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.846794e-01 | 0.734 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 1.545234e-01 | 0.811 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.760071e-01 | 0.559 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 2.760071e-01 | 0.559 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.760071e-01 | 0.559 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 2.760071e-01 | 0.559 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 2.760071e-01 | 0.559 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 2.760071e-01 | 0.559 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.301652e-01 | 0.886 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 2.222269e-01 | 0.653 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 2.222269e-01 | 0.653 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 2.222269e-01 | 0.653 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 1.828192e-01 | 0.738 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 1.828192e-01 | 0.738 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.828192e-01 | 0.738 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 1.828192e-01 | 0.738 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 1.523839e-01 | 0.817 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 1.473329e-01 | 0.832 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.473329e-01 | 0.832 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 1.760539e-01 | 0.754 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 1.760539e-01 | 0.754 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 1.760539e-01 | 0.754 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.760539e-01 | 0.754 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 2.126484e-01 | 0.672 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.126484e-01 | 0.672 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 2.126484e-01 | 0.672 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 2.610994e-01 | 0.583 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 2.610994e-01 | 0.583 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 2.610994e-01 | 0.583 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 3.299337e-01 | 0.482 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 3.299337e-01 | 0.482 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.299337e-01 | 0.482 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 3.299337e-01 | 0.482 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 3.299337e-01 | 0.482 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.299337e-01 | 0.482 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 3.299337e-01 | 0.482 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 3.299337e-01 | 0.482 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 3.299337e-01 | 0.482 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 3.299337e-01 | 0.482 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 4.455491e-01 | 0.351 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 4.455491e-01 | 0.351 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 4.455491e-01 | 0.351 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 4.455491e-01 | 0.351 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 4.455491e-01 | 0.351 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 4.455491e-01 | 0.351 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 4.455491e-01 | 0.351 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 4.455491e-01 | 0.351 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 4.455491e-01 | 0.351 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.010058e-01 | 0.697 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 2.010058e-01 | 0.697 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.010058e-01 | 0.697 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 2.437030e-01 | 0.613 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 2.437030e-01 | 0.613 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 2.437030e-01 | 0.613 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 2.437030e-01 | 0.613 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 1.892138e-01 | 0.723 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 3.007369e-01 | 0.522 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 3.007369e-01 | 0.522 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 2.270595e-01 | 0.644 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 2.270595e-01 | 0.644 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 1.341250e-01 | 0.872 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.671566e-01 | 0.777 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 3.826859e-01 | 0.417 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.826859e-01 | 0.417 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 3.826859e-01 | 0.417 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 3.826859e-01 | 0.417 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 1.571263e-01 | 0.804 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 2.540287e-01 | 0.595 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 3.406382e-01 | 0.468 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 3.406382e-01 | 0.468 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 3.406382e-01 | 0.468 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 3.406382e-01 | 0.468 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 3.406382e-01 | 0.468 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 3.406382e-01 | 0.468 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 3.406382e-01 | 0.468 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 3.406382e-01 | 0.468 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.620791e-01 | 0.790 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.620791e-01 | 0.790 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 1.620791e-01 | 0.790 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.082796e-01 | 0.511 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 2.591406e-01 | 0.586 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.394909e-01 | 0.621 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.394909e-01 | 0.621 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 1.926200e-01 | 0.715 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 1.926200e-01 | 0.715 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 1.926200e-01 | 0.715 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.479610e-01 | 0.830 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.389497e-01 | 0.857 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.818930e-01 | 0.740 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.614149e-01 | 0.583 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.838465e-01 | 0.547 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 2.838465e-01 | 0.547 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 2.838465e-01 | 0.547 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.099644e-01 | 0.509 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 3.099644e-01 | 0.509 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.099644e-01 | 0.509 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 3.412287e-01 | 0.467 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 3.803650e-01 | 0.420 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 3.803650e-01 | 0.420 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 3.803650e-01 | 0.420 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 4.335724e-01 | 0.363 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 4.335724e-01 | 0.363 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 4.335724e-01 | 0.363 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 4.335724e-01 | 0.363 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 4.335724e-01 | 0.363 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 4.335724e-01 | 0.363 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 4.335724e-01 | 0.363 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 5.215694e-01 | 0.283 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 5.215694e-01 | 0.283 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 5.215694e-01 | 0.283 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 5.215694e-01 | 0.283 | 0 | 0 |
| Defective GSS causes GSS deficiency | R-HSA-5579006 | 5.215694e-01 | 0.283 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 1.714667e-01 | 0.766 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 1.714667e-01 | 0.766 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 2.254689e-01 | 0.647 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.838743e-01 | 0.547 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 2.838743e-01 | 0.547 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 2.838743e-01 | 0.547 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 3.385637e-01 | 0.470 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 3.385637e-01 | 0.470 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 2.104170e-01 | 0.677 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 3.742669e-01 | 0.427 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 3.742669e-01 | 0.427 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.351892e-01 | 0.869 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 2.602941e-01 | 0.585 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.345789e-01 | 0.476 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 4.195419e-01 | 0.377 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 4.195419e-01 | 0.377 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 4.195419e-01 | 0.377 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 4.195419e-01 | 0.377 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 4.195419e-01 | 0.377 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 4.195419e-01 | 0.377 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 4.195419e-01 | 0.377 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 4.195419e-01 | 0.377 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 4.195419e-01 | 0.377 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.673503e-01 | 0.435 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 3.603514e-01 | 0.443 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 3.603514e-01 | 0.443 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 4.071583e-01 | 0.390 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 4.821136e-01 | 0.317 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.861765e-01 | 0.730 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.714715e-01 | 0.766 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 3.961606e-01 | 0.402 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 3.961606e-01 | 0.402 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.375378e-01 | 0.862 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 2.197723e-01 | 0.658 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 2.197723e-01 | 0.658 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.862318e-01 | 0.413 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.862318e-01 | 0.413 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 4.578553e-01 | 0.339 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.806184e-01 | 0.743 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 4.396910e-01 | 0.357 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 4.396910e-01 | 0.357 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 4.396910e-01 | 0.357 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.120231e-01 | 0.506 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 3.906956e-01 | 0.408 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 3.434301e-01 | 0.464 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 3.250216e-01 | 0.488 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.215270e-01 | 0.493 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 3.215270e-01 | 0.493 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 3.668272e-01 | 0.436 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 3.831668e-01 | 0.417 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.532544e-01 | 0.344 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 4.716784e-01 | 0.326 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 4.716784e-01 | 0.326 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 4.950489e-01 | 0.305 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 4.950489e-01 | 0.305 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 5.279961e-01 | 0.277 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 5.279961e-01 | 0.277 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.871705e-01 | 0.231 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 5.871705e-01 | 0.231 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 5.871705e-01 | 0.231 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.871705e-01 | 0.231 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 5.871705e-01 | 0.231 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 5.871705e-01 | 0.231 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 4.116653e-01 | 0.385 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 4.116653e-01 | 0.385 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.832403e-01 | 0.417 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.634016e-01 | 0.334 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 4.311202e-01 | 0.365 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 3.969763e-01 | 0.401 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 4.505323e-01 | 0.346 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 5.309195e-01 | 0.275 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 5.309195e-01 | 0.275 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.309195e-01 | 0.275 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.309195e-01 | 0.275 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.309195e-01 | 0.275 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 5.309195e-01 | 0.275 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 5.309195e-01 | 0.275 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 4.698569e-01 | 0.328 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.614555e-01 | 0.336 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 5.710365e-01 | 0.243 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 5.710365e-01 | 0.243 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 4.847143e-01 | 0.315 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 4.810874e-01 | 0.318 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 5.356777e-01 | 0.271 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 5.356777e-01 | 0.271 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 5.209194e-01 | 0.283 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 5.209194e-01 | 0.283 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 5.080103e-01 | 0.294 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 5.653119e-01 | 0.248 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 5.653119e-01 | 0.248 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 5.653119e-01 | 0.248 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.418087e-01 | 0.266 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 5.436710e-01 | 0.265 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 5.841754e-01 | 0.233 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 5.873171e-01 | 0.231 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 5.873171e-01 | 0.231 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 5.981135e-01 | 0.223 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 5.981135e-01 | 0.223 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 6.111516e-01 | 0.214 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 6.437797e-01 | 0.191 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 6.437797e-01 | 0.191 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 6.437797e-01 | 0.191 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 6.437797e-01 | 0.191 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 6.437797e-01 | 0.191 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 6.437797e-01 | 0.191 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 6.043251e-01 | 0.219 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 6.074445e-01 | 0.216 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 6.074445e-01 | 0.216 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.151190e-01 | 0.211 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.151190e-01 | 0.211 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 6.186062e-01 | 0.209 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 6.186062e-01 | 0.209 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 6.186062e-01 | 0.209 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 6.335757e-01 | 0.198 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 6.292486e-01 | 0.201 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 6.292486e-01 | 0.201 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 6.447378e-01 | 0.191 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 6.483343e-01 | 0.188 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 6.483343e-01 | 0.188 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 1.607266e-01 | 0.794 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.988667e-01 | 0.701 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 1.770422e-01 | 0.752 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.634016e-01 | 0.334 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 4.545190e-01 | 0.342 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 2.254302e-01 | 0.647 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 3.742669e-01 | 0.427 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 4.545190e-01 | 0.342 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 1.341250e-01 | 0.872 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.257467e-01 | 0.646 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.104170e-01 | 0.677 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 3.906956e-01 | 0.408 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 5.618530e-01 | 0.250 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 2.417849e-01 | 0.617 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 4.977848e-01 | 0.303 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 3.099644e-01 | 0.509 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 5.628726e-01 | 0.250 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 2.335618e-01 | 0.632 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 4.322098e-01 | 0.364 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 4.977848e-01 | 0.303 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 4.977848e-01 | 0.303 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.673503e-01 | 0.435 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 5.134642e-01 | 0.289 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 5.710365e-01 | 0.243 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.818930e-01 | 0.740 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 2.614149e-01 | 0.583 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.524484e-01 | 0.817 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 4.346551e-01 | 0.362 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.569920e-01 | 0.340 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.426569e-01 | 0.615 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.426569e-01 | 0.615 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 6.074445e-01 | 0.216 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.235840e-01 | 0.651 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.906002e-01 | 0.720 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 3.906956e-01 | 0.408 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 5.653119e-01 | 0.248 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 6.111754e-01 | 0.214 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 3.300139e-01 | 0.481 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.408117e-01 | 0.618 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.148261e-01 | 0.288 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.976428e-01 | 0.303 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.119240e-01 | 0.213 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 5.209194e-01 | 0.283 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 6.356534e-01 | 0.197 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 1.545234e-01 | 0.811 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 2.610994e-01 | 0.583 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.090355e-01 | 0.510 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.620135e-01 | 0.790 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.481022e-01 | 0.349 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 5.710365e-01 | 0.243 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 5.080751e-01 | 0.294 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 6.447378e-01 | 0.191 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 6.483343e-01 | 0.188 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.426901e-01 | 0.615 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.621795e-01 | 0.790 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 2.126484e-01 | 0.672 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.935633e-01 | 0.307 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 5.356777e-01 | 0.271 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.742669e-01 | 0.427 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 3.593696e-01 | 0.444 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 3.300139e-01 | 0.481 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 3.019758e-01 | 0.520 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.835946e-01 | 0.416 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 3.299337e-01 | 0.482 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 4.335724e-01 | 0.363 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 3.687340e-01 | 0.433 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 5.279961e-01 | 0.277 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 5.309195e-01 | 0.275 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 4.614555e-01 | 0.336 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 5.710365e-01 | 0.243 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 5.710365e-01 | 0.243 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 5.653119e-01 | 0.248 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 6.111516e-01 | 0.214 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.838743e-01 | 0.547 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 4.439366e-01 | 0.353 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 5.342710e-01 | 0.272 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 5.873171e-01 | 0.231 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 6.119240e-01 | 0.213 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 4.782227e-01 | 0.320 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 1.301652e-01 | 0.886 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 6.483343e-01 | 0.188 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 5.664511e-01 | 0.247 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 1.420546e-01 | 0.848 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 6.119240e-01 | 0.213 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.156916e-01 | 0.288 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 3.603514e-01 | 0.443 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 5.831010e-01 | 0.234 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.190227e-01 | 0.660 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.572738e-01 | 0.447 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.574554e-01 | 0.447 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 2.760071e-01 | 0.559 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 2.222269e-01 | 0.653 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 2.610994e-01 | 0.583 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 2.437030e-01 | 0.613 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.437030e-01 | 0.613 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 4.195419e-01 | 0.377 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 4.821136e-01 | 0.317 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 3.961606e-01 | 0.402 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.961606e-01 | 0.402 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 4.248419e-01 | 0.372 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 3.906956e-01 | 0.408 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.871705e-01 | 0.231 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 4.004387e-01 | 0.397 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 5.309195e-01 | 0.275 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.434705e-01 | 0.843 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.434705e-01 | 0.843 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 5.209194e-01 | 0.283 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 3.406382e-01 | 0.468 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.116347e-01 | 0.291 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 4.016108e-01 | 0.396 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 2.099618e-01 | 0.678 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.547641e-01 | 0.810 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.807467e-01 | 0.552 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.345789e-01 | 0.476 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 4.008478e-01 | 0.397 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 6.005184e-01 | 0.221 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.378619e-01 | 0.359 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 2.417849e-01 | 0.617 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 4.146235e-01 | 0.382 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.385637e-01 | 0.470 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 2.425818e-01 | 0.615 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 3.750091e-01 | 0.426 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.399750e-01 | 0.194 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 4.812712e-01 | 0.318 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.729371e-01 | 0.762 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 4.636582e-01 | 0.334 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 4.636582e-01 | 0.334 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 6.446898e-01 | 0.191 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.730763e-01 | 0.325 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 3.087932e-01 | 0.510 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.760071e-01 | 0.559 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 1.760539e-01 | 0.754 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 1.760539e-01 | 0.754 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 1.760539e-01 | 0.754 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 2.610994e-01 | 0.583 | 0 | 0 |
| Transcription from mitochondrial promoters | R-HSA-75944 | 4.455491e-01 | 0.351 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 2.540287e-01 | 0.595 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 2.104170e-01 | 0.677 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 2.104170e-01 | 0.677 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 2.104170e-01 | 0.677 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 2.104170e-01 | 0.677 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.069592e-01 | 0.684 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 4.950489e-01 | 0.305 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 5.279961e-01 | 0.277 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 5.029588e-01 | 0.298 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.357581e-01 | 0.361 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 5.333948e-01 | 0.273 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 6.437797e-01 | 0.191 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 6.186062e-01 | 0.209 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.203077e-01 | 0.494 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 4.054800e-01 | 0.392 | 0 | 0 |
| Kinesins | R-HSA-983189 | 3.058311e-01 | 0.515 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.608869e-01 | 0.443 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.671566e-01 | 0.777 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.294440e-01 | 0.201 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.890830e-01 | 0.723 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.498808e-01 | 0.824 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 4.956338e-01 | 0.305 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.698569e-01 | 0.328 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 4.380363e-01 | 0.358 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.918727e-01 | 0.717 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.572738e-01 | 0.447 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.773360e-01 | 0.751 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 3.299337e-01 | 0.482 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 5.215694e-01 | 0.283 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.961606e-01 | 0.402 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 5.279961e-01 | 0.277 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 5.281553e-01 | 0.277 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 5.975386e-01 | 0.224 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.292486e-01 | 0.201 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 6.483343e-01 | 0.188 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.104155e-01 | 0.677 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.104155e-01 | 0.677 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 2.797843e-01 | 0.553 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.358845e-01 | 0.627 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.419927e-01 | 0.848 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.936680e-01 | 0.307 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.977708e-01 | 0.223 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.678094e-01 | 0.572 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 5.398643e-01 | 0.268 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 3.826859e-01 | 0.417 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 3.826859e-01 | 0.417 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 4.716784e-01 | 0.326 | 0 | 0 |
| Vasopressin-like receptors | R-HSA-388479 | 5.871705e-01 | 0.231 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.727827e-01 | 0.429 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.636354e-01 | 0.439 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 2.221270e-01 | 0.653 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 5.637530e-01 | 0.249 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 6.447378e-01 | 0.191 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 1.681337e-01 | 0.774 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 4.071583e-01 | 0.390 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 4.071583e-01 | 0.390 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 5.279961e-01 | 0.277 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.292486e-01 | 0.201 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 3.837907e-01 | 0.416 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 5.087788e-01 | 0.293 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 6.447378e-01 | 0.191 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 6.447378e-01 | 0.191 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 4.698569e-01 | 0.328 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.019998e-01 | 0.396 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 4.431803e-01 | 0.353 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 5.087788e-01 | 0.293 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 5.333948e-01 | 0.273 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 5.333948e-01 | 0.273 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 5.564070e-01 | 0.255 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 3.574554e-01 | 0.447 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.760071e-01 | 0.559 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 2.610994e-01 | 0.583 | 0 | 0 |
| Sensory perception of salty taste | R-HSA-9730628 | 3.299337e-01 | 0.482 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 4.455491e-01 | 0.351 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 4.455491e-01 | 0.351 | 0 | 0 |
| TGFBR3 regulates activin signaling | R-HSA-9839406 | 4.455491e-01 | 0.351 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.007369e-01 | 0.522 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 2.756782e-01 | 0.560 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 2.221270e-01 | 0.653 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 3.803650e-01 | 0.420 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 3.803650e-01 | 0.420 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 4.335724e-01 | 0.363 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 5.215694e-01 | 0.283 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 4.821136e-01 | 0.317 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 4.396910e-01 | 0.357 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 2.794142e-01 | 0.554 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 5.871705e-01 | 0.231 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 5.871705e-01 | 0.231 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.309195e-01 | 0.275 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 5.087788e-01 | 0.293 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 6.111516e-01 | 0.214 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 6.437797e-01 | 0.191 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 6.437797e-01 | 0.191 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 6.437797e-01 | 0.191 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.977370e-01 | 0.223 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 6.292486e-01 | 0.201 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.292486e-01 | 0.201 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.356534e-01 | 0.197 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 4.601145e-01 | 0.337 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 2.807467e-01 | 0.552 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 2.104170e-01 | 0.677 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 3.405005e-01 | 0.468 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.673503e-01 | 0.435 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 5.398643e-01 | 0.268 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 4.950489e-01 | 0.305 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 3.276384e-01 | 0.485 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 5.309195e-01 | 0.275 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 1.523839e-01 | 0.817 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.270595e-01 | 0.644 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 1.770422e-01 | 0.752 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 2.429362e-01 | 0.615 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.637530e-01 | 0.249 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 2.543137e-01 | 0.595 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 2.543137e-01 | 0.595 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.674195e-01 | 0.246 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 3.336514e-01 | 0.477 | 0 | 0 |
| MDK and PTN in ALK signaling | R-HSA-9851151 | 5.871705e-01 | 0.231 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 5.333948e-01 | 0.273 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 5.981135e-01 | 0.223 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 5.985940e-01 | 0.223 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.700795e-01 | 0.769 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.156605e-01 | 0.666 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 3.357812e-01 | 0.474 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 2.222269e-01 | 0.653 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.299337e-01 | 0.482 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 4.248419e-01 | 0.372 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 5.309195e-01 | 0.275 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 6.437797e-01 | 0.191 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 6.483343e-01 | 0.188 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 3.203077e-01 | 0.494 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 4.121049e-01 | 0.385 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 5.598724e-01 | 0.252 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.595436e-01 | 0.797 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 4.396910e-01 | 0.357 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 6.247285e-01 | 0.204 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 5.333948e-01 | 0.273 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 5.209194e-01 | 0.283 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 5.355228e-01 | 0.271 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.603514e-01 | 0.443 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.574554e-01 | 0.447 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 1.523839e-01 | 0.817 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 4.455491e-01 | 0.351 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 3.007369e-01 | 0.522 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.477637e-01 | 0.830 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 3.412287e-01 | 0.467 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 5.215694e-01 | 0.283 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 3.535019e-01 | 0.452 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 4.950489e-01 | 0.305 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.279961e-01 | 0.277 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 5.871705e-01 | 0.231 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 4.782227e-01 | 0.320 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 4.716372e-01 | 0.326 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 5.981135e-01 | 0.223 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.981135e-01 | 0.223 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 6.111516e-01 | 0.214 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.043251e-01 | 0.219 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 2.807467e-01 | 0.552 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 5.029588e-01 | 0.298 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.178996e-01 | 0.286 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 3.082796e-01 | 0.511 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 2.838743e-01 | 0.547 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 4.950489e-01 | 0.305 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 4.714923e-01 | 0.327 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 1.965717e-01 | 0.706 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 3.412287e-01 | 0.467 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 4.335724e-01 | 0.363 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 4.335724e-01 | 0.363 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 5.871705e-01 | 0.231 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 5.871705e-01 | 0.231 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 6.483343e-01 | 0.188 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 3.603514e-01 | 0.443 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 3.345789e-01 | 0.476 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 2.626431e-01 | 0.581 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 3.961606e-01 | 0.402 | 0 | 0 |
| ATF6B (ATF6-beta) activates chaperones | R-HSA-8874177 | 4.455491e-01 | 0.351 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 5.378258e-01 | 0.269 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 6.437797e-01 | 0.191 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 6.483343e-01 | 0.188 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.812712e-01 | 0.318 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.009929e-01 | 0.697 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 4.396910e-01 | 0.357 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.292486e-01 | 0.201 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.594876e-01 | 0.797 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 6.437797e-01 | 0.191 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.698569e-01 | 0.328 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 6.437797e-01 | 0.191 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 5.710365e-01 | 0.243 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 6.514784e-01 | 0.186 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 6.536753e-01 | 0.185 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.548891e-01 | 0.184 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 6.581249e-01 | 0.182 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 6.584677e-01 | 0.181 | 0 | 0 |
| PKA activation | R-HSA-163615 | 6.586739e-01 | 0.181 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 6.586739e-01 | 0.181 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.586739e-01 | 0.181 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 6.586739e-01 | 0.181 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 6.625748e-01 | 0.179 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 6.626589e-01 | 0.179 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 6.662823e-01 | 0.176 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 6.749469e-01 | 0.171 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 6.757243e-01 | 0.170 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 6.769516e-01 | 0.169 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 6.792330e-01 | 0.168 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 6.803399e-01 | 0.167 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 6.822455e-01 | 0.166 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.826345e-01 | 0.166 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 6.826345e-01 | 0.166 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 6.826345e-01 | 0.166 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 6.826345e-01 | 0.166 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 6.826345e-01 | 0.166 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 6.826345e-01 | 0.166 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 6.826345e-01 | 0.166 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 6.826345e-01 | 0.166 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 6.826345e-01 | 0.166 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 6.826345e-01 | 0.166 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 6.826345e-01 | 0.166 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.863733e-01 | 0.163 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 6.863733e-01 | 0.163 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 6.863733e-01 | 0.163 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 6.867600e-01 | 0.163 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.926293e-01 | 0.159 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 6.926293e-01 | 0.159 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.926293e-01 | 0.159 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.926293e-01 | 0.159 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 6.926293e-01 | 0.159 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.926293e-01 | 0.159 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 6.926293e-01 | 0.159 | 0 | 0 |
| Ligand-receptor interactions | R-HSA-5632681 | 6.926293e-01 | 0.159 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.926293e-01 | 0.159 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.926293e-01 | 0.159 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.926293e-01 | 0.159 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 6.926293e-01 | 0.159 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 6.926293e-01 | 0.159 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 6.926293e-01 | 0.159 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 6.926293e-01 | 0.159 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 6.927571e-01 | 0.159 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 6.933494e-01 | 0.159 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 6.933494e-01 | 0.159 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.933494e-01 | 0.159 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 6.948501e-01 | 0.158 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.969895e-01 | 0.157 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.001171e-01 | 0.155 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 7.025495e-01 | 0.153 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 7.025495e-01 | 0.153 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 7.042619e-01 | 0.152 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 7.075415e-01 | 0.150 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 7.093355e-01 | 0.149 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 7.123532e-01 | 0.147 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 7.123532e-01 | 0.147 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 7.123532e-01 | 0.147 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 7.141435e-01 | 0.146 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 7.141435e-01 | 0.146 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 7.141435e-01 | 0.146 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 7.141435e-01 | 0.146 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 7.141435e-01 | 0.146 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 7.141435e-01 | 0.146 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 7.141435e-01 | 0.146 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 7.141435e-01 | 0.146 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 7.141435e-01 | 0.146 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 7.154983e-01 | 0.145 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 7.158013e-01 | 0.145 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 7.158013e-01 | 0.145 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.158013e-01 | 0.145 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 7.163265e-01 | 0.145 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 7.173156e-01 | 0.144 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 7.187447e-01 | 0.143 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 7.211946e-01 | 0.142 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.211946e-01 | 0.142 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 7.211946e-01 | 0.142 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 7.211946e-01 | 0.142 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 7.215369e-01 | 0.142 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 7.250768e-01 | 0.140 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.250768e-01 | 0.140 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 7.273707e-01 | 0.138 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 7.319405e-01 | 0.136 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 7.319405e-01 | 0.136 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 7.319405e-01 | 0.136 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 7.319405e-01 | 0.136 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 7.347823e-01 | 0.134 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 7.347823e-01 | 0.134 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 7.347823e-01 | 0.134 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 7.347823e-01 | 0.134 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 7.347823e-01 | 0.134 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 7.347823e-01 | 0.134 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 7.347823e-01 | 0.134 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 7.347823e-01 | 0.134 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 7.347823e-01 | 0.134 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 7.347823e-01 | 0.134 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 7.347823e-01 | 0.134 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 7.347823e-01 | 0.134 | 0 | 0 |
| CREB3 factors activate genes | R-HSA-8874211 | 7.347823e-01 | 0.134 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 7.366391e-01 | 0.133 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 7.366391e-01 | 0.133 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 7.366391e-01 | 0.133 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 7.370189e-01 | 0.133 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.397938e-01 | 0.131 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 7.401664e-01 | 0.131 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 7.401664e-01 | 0.131 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 7.429816e-01 | 0.129 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 7.429816e-01 | 0.129 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 7.429816e-01 | 0.129 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 7.429816e-01 | 0.129 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 7.429816e-01 | 0.129 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 7.429816e-01 | 0.129 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 7.467973e-01 | 0.127 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 7.506599e-01 | 0.125 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 7.509621e-01 | 0.124 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 7.531172e-01 | 0.123 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 7.536445e-01 | 0.123 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 7.536445e-01 | 0.123 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.539906e-01 | 0.123 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.570163e-01 | 0.121 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 7.570163e-01 | 0.121 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.570163e-01 | 0.121 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.570163e-01 | 0.121 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 7.581725e-01 | 0.120 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 7.581725e-01 | 0.120 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 7.581725e-01 | 0.120 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 7.592714e-01 | 0.120 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 7.592714e-01 | 0.120 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.592714e-01 | 0.120 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 7.592714e-01 | 0.120 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 7.598372e-01 | 0.119 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 7.610392e-01 | 0.119 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 7.648217e-01 | 0.116 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.660469e-01 | 0.116 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 7.691052e-01 | 0.114 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.692887e-01 | 0.114 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.692887e-01 | 0.114 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 7.692887e-01 | 0.114 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 7.692887e-01 | 0.114 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 7.692887e-01 | 0.114 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 7.692887e-01 | 0.114 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.692887e-01 | 0.114 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 7.711566e-01 | 0.113 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.711566e-01 | 0.113 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 7.711566e-01 | 0.113 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 7.711566e-01 | 0.113 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 7.711566e-01 | 0.113 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 7.711566e-01 | 0.113 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 7.711566e-01 | 0.113 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 7.711566e-01 | 0.113 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 7.711566e-01 | 0.113 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 7.711566e-01 | 0.113 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 7.711566e-01 | 0.113 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 7.711566e-01 | 0.113 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 7.711566e-01 | 0.113 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 7.711566e-01 | 0.113 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 7.711566e-01 | 0.113 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 7.711566e-01 | 0.113 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 7.711566e-01 | 0.113 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.711566e-01 | 0.113 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.711566e-01 | 0.113 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.752241e-01 | 0.111 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 7.752241e-01 | 0.111 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 7.766805e-01 | 0.110 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.766805e-01 | 0.110 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 7.783345e-01 | 0.109 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 7.792956e-01 | 0.108 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.832309e-01 | 0.106 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.832309e-01 | 0.106 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 7.862929e-01 | 0.104 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 7.902302e-01 | 0.102 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 7.915388e-01 | 0.102 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.915388e-01 | 0.102 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 7.930976e-01 | 0.101 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 7.932165e-01 | 0.101 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.932165e-01 | 0.101 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 7.932165e-01 | 0.101 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 7.934477e-01 | 0.100 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 7.954902e-01 | 0.099 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 7.997936e-01 | 0.097 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 7.997936e-01 | 0.097 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 8.025440e-01 | 0.096 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 8.025440e-01 | 0.096 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 8.025440e-01 | 0.096 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 8.025440e-01 | 0.096 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 8.025440e-01 | 0.096 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 8.025440e-01 | 0.096 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 8.025440e-01 | 0.096 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 8.025440e-01 | 0.096 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 8.025440e-01 | 0.096 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 8.025440e-01 | 0.096 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 8.025440e-01 | 0.096 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 8.025596e-01 | 0.096 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 8.056274e-01 | 0.094 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 8.062373e-01 | 0.094 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 8.100030e-01 | 0.092 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 8.126126e-01 | 0.090 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 8.149226e-01 | 0.089 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 8.149226e-01 | 0.089 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 8.149226e-01 | 0.089 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 8.149226e-01 | 0.089 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.149226e-01 | 0.089 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.149226e-01 | 0.089 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 8.149226e-01 | 0.089 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.178131e-01 | 0.087 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 8.178131e-01 | 0.087 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 8.185595e-01 | 0.087 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 8.187265e-01 | 0.087 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 8.189629e-01 | 0.087 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 8.189629e-01 | 0.087 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 8.189629e-01 | 0.087 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 8.208364e-01 | 0.086 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 8.208364e-01 | 0.086 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 8.208364e-01 | 0.086 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 8.208364e-01 | 0.086 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 8.208364e-01 | 0.086 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 8.208364e-01 | 0.086 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 8.210889e-01 | 0.086 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.253518e-01 | 0.083 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 8.253518e-01 | 0.083 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 8.265566e-01 | 0.083 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 8.296280e-01 | 0.081 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 8.296280e-01 | 0.081 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 8.296280e-01 | 0.081 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 8.296280e-01 | 0.081 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 8.296280e-01 | 0.081 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 8.296280e-01 | 0.081 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 8.296280e-01 | 0.081 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 8.296280e-01 | 0.081 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 8.307361e-01 | 0.081 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 8.315641e-01 | 0.080 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.342738e-01 | 0.079 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.344335e-01 | 0.079 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.344335e-01 | 0.079 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.344335e-01 | 0.079 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 8.344335e-01 | 0.079 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.345664e-01 | 0.079 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 8.345664e-01 | 0.079 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 8.397072e-01 | 0.076 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 8.418106e-01 | 0.075 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 8.419582e-01 | 0.075 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.419582e-01 | 0.075 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 8.445191e-01 | 0.073 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.445191e-01 | 0.073 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 8.458939e-01 | 0.073 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 8.459990e-01 | 0.073 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.468755e-01 | 0.072 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.468755e-01 | 0.072 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 8.473473e-01 | 0.072 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 8.497304e-01 | 0.071 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.497304e-01 | 0.071 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 8.499641e-01 | 0.071 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 8.523050e-01 | 0.069 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 8.523050e-01 | 0.069 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 8.523050e-01 | 0.069 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 8.523050e-01 | 0.069 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 8.523050e-01 | 0.069 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 8.523050e-01 | 0.069 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 8.524383e-01 | 0.069 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 8.529983e-01 | 0.069 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 8.529983e-01 | 0.069 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 8.529983e-01 | 0.069 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 8.529983e-01 | 0.069 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 8.529983e-01 | 0.069 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 8.529983e-01 | 0.069 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 8.529983e-01 | 0.069 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 8.529983e-01 | 0.069 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 8.529983e-01 | 0.069 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 8.529983e-01 | 0.069 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 8.529983e-01 | 0.069 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 8.529983e-01 | 0.069 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 8.529983e-01 | 0.069 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 8.529983e-01 | 0.069 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 8.529983e-01 | 0.069 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.530584e-01 | 0.069 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 8.530584e-01 | 0.069 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 8.530584e-01 | 0.069 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 8.530584e-01 | 0.069 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 8.546494e-01 | 0.068 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.546494e-01 | 0.068 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 8.569683e-01 | 0.067 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 8.586734e-01 | 0.066 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 8.586734e-01 | 0.066 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.606524e-01 | 0.065 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.612782e-01 | 0.065 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.637807e-01 | 0.064 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.637807e-01 | 0.064 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.637807e-01 | 0.064 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 8.637807e-01 | 0.064 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 8.641786e-01 | 0.063 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 8.651803e-01 | 0.063 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 8.651803e-01 | 0.063 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 8.654528e-01 | 0.063 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.654528e-01 | 0.063 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 8.666830e-01 | 0.062 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 8.682914e-01 | 0.061 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 8.682914e-01 | 0.061 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 8.682914e-01 | 0.061 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 8.682914e-01 | 0.061 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 8.682914e-01 | 0.061 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 8.682914e-01 | 0.061 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 8.682914e-01 | 0.061 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 8.682914e-01 | 0.061 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 8.692037e-01 | 0.061 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 8.731641e-01 | 0.059 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.731641e-01 | 0.059 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.731641e-01 | 0.059 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 8.731641e-01 | 0.059 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.731641e-01 | 0.059 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 8.731641e-01 | 0.059 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 8.731641e-01 | 0.059 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 8.731641e-01 | 0.059 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 8.750698e-01 | 0.058 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 8.750698e-01 | 0.058 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 8.750698e-01 | 0.058 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 8.766613e-01 | 0.057 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 8.769387e-01 | 0.057 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 8.769387e-01 | 0.057 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 8.769387e-01 | 0.057 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 8.788921e-01 | 0.056 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 8.799910e-01 | 0.056 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 8.808856e-01 | 0.055 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 8.826725e-01 | 0.054 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 8.826725e-01 | 0.054 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 8.826725e-01 | 0.054 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.826725e-01 | 0.054 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.843438e-01 | 0.053 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.843438e-01 | 0.053 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 8.852582e-01 | 0.053 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 8.868075e-01 | 0.052 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.874275e-01 | 0.052 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 8.875651e-01 | 0.052 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.875651e-01 | 0.052 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 8.875651e-01 | 0.052 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 8.875651e-01 | 0.052 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 8.884486e-01 | 0.051 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 8.884486e-01 | 0.051 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 8.885329e-01 | 0.051 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.892896e-01 | 0.051 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.895795e-01 | 0.051 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.895795e-01 | 0.051 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 8.895795e-01 | 0.051 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 8.905645e-01 | 0.050 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 8.905645e-01 | 0.050 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.905645e-01 | 0.050 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 8.905645e-01 | 0.050 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.905645e-01 | 0.050 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 8.905645e-01 | 0.050 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 8.905645e-01 | 0.050 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 8.912675e-01 | 0.050 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.922924e-01 | 0.049 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.955877e-01 | 0.048 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 8.955877e-01 | 0.048 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 8.955877e-01 | 0.048 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 8.971891e-01 | 0.047 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 8.972266e-01 | 0.047 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.978082e-01 | 0.047 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 8.978082e-01 | 0.047 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 8.983329e-01 | 0.047 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 8.983329e-01 | 0.047 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 8.996518e-01 | 0.046 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 9.032612e-01 | 0.044 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 9.033967e-01 | 0.044 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.046054e-01 | 0.044 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.047164e-01 | 0.043 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 9.055786e-01 | 0.043 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 9.055786e-01 | 0.043 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 9.055786e-01 | 0.043 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 9.055786e-01 | 0.043 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 9.055786e-01 | 0.043 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 9.064331e-01 | 0.043 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 9.064331e-01 | 0.043 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 9.071685e-01 | 0.042 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 9.071685e-01 | 0.042 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 9.071685e-01 | 0.042 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 9.071685e-01 | 0.042 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 9.071685e-01 | 0.042 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 9.071685e-01 | 0.042 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.071685e-01 | 0.042 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 9.084656e-01 | 0.042 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.090392e-01 | 0.041 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 9.147699e-01 | 0.039 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.148545e-01 | 0.039 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 9.175379e-01 | 0.037 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.175379e-01 | 0.037 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 9.175379e-01 | 0.037 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 9.175379e-01 | 0.037 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.175379e-01 | 0.037 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.179844e-01 | 0.037 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 9.185336e-01 | 0.037 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 9.185336e-01 | 0.037 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 9.185336e-01 | 0.037 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 9.185336e-01 | 0.037 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 9.185336e-01 | 0.037 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 9.185336e-01 | 0.037 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 9.185336e-01 | 0.037 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 9.185336e-01 | 0.037 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 9.185336e-01 | 0.037 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 9.186407e-01 | 0.037 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.196259e-01 | 0.036 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 9.208180e-01 | 0.036 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.208574e-01 | 0.036 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.216076e-01 | 0.035 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.224368e-01 | 0.035 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 9.245342e-01 | 0.034 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.249869e-01 | 0.034 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.261195e-01 | 0.033 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 9.268103e-01 | 0.033 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.268103e-01 | 0.033 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 9.268103e-01 | 0.033 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.268103e-01 | 0.033 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 9.294783e-01 | 0.032 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.294783e-01 | 0.032 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 9.294783e-01 | 0.032 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.294783e-01 | 0.032 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 9.297118e-01 | 0.032 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 9.297118e-01 | 0.032 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 9.297118e-01 | 0.032 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 9.297118e-01 | 0.032 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 9.297118e-01 | 0.032 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.302209e-01 | 0.031 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 9.335077e-01 | 0.030 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.335077e-01 | 0.030 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.335077e-01 | 0.030 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.335077e-01 | 0.030 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.338748e-01 | 0.030 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 9.340437e-01 | 0.030 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.350913e-01 | 0.029 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.350913e-01 | 0.029 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.350913e-01 | 0.029 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.387215e-01 | 0.027 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 9.393567e-01 | 0.027 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 9.393567e-01 | 0.027 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 9.393567e-01 | 0.027 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.393567e-01 | 0.027 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 9.393567e-01 | 0.027 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 9.393567e-01 | 0.027 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.393567e-01 | 0.027 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 9.393567e-01 | 0.027 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 9.393567e-01 | 0.027 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 9.393567e-01 | 0.027 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.393567e-01 | 0.027 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.395458e-01 | 0.027 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 9.398168e-01 | 0.027 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 9.399286e-01 | 0.027 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 9.399286e-01 | 0.027 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 9.399286e-01 | 0.027 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 9.401387e-01 | 0.027 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.402089e-01 | 0.027 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.402089e-01 | 0.027 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 9.402089e-01 | 0.027 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.418538e-01 | 0.026 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.424785e-01 | 0.026 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.424785e-01 | 0.026 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.424785e-01 | 0.026 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.424785e-01 | 0.026 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 9.424785e-01 | 0.026 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 9.424785e-01 | 0.026 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 9.424785e-01 | 0.026 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.444588e-01 | 0.025 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 9.447586e-01 | 0.025 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 9.447586e-01 | 0.025 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 9.454201e-01 | 0.024 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 9.454201e-01 | 0.024 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 9.456859e-01 | 0.024 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 9.458111e-01 | 0.024 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.462796e-01 | 0.024 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 9.470232e-01 | 0.024 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 9.471740e-01 | 0.024 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.472678e-01 | 0.024 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.472678e-01 | 0.024 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.476787e-01 | 0.023 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 9.476787e-01 | 0.023 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 9.476787e-01 | 0.023 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.476787e-01 | 0.023 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 9.476787e-01 | 0.023 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 9.476787e-01 | 0.023 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.476787e-01 | 0.023 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.490586e-01 | 0.023 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.490611e-01 | 0.023 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 9.490611e-01 | 0.023 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.490611e-01 | 0.023 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.490611e-01 | 0.023 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 9.500806e-01 | 0.022 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 9.514031e-01 | 0.022 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 9.517727e-01 | 0.021 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.517727e-01 | 0.021 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.517727e-01 | 0.021 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.522161e-01 | 0.021 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.522161e-01 | 0.021 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.522161e-01 | 0.021 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.522161e-01 | 0.021 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.528992e-01 | 0.021 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 9.548590e-01 | 0.020 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.548590e-01 | 0.020 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 9.548590e-01 | 0.020 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.548590e-01 | 0.020 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.548590e-01 | 0.020 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 9.548590e-01 | 0.020 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 9.548590e-01 | 0.020 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.548590e-01 | 0.020 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 9.549208e-01 | 0.020 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 9.549208e-01 | 0.020 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.549208e-01 | 0.020 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.549208e-01 | 0.020 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.549208e-01 | 0.020 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.567375e-01 | 0.019 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.567375e-01 | 0.019 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.567375e-01 | 0.019 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 9.583463e-01 | 0.018 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.600735e-01 | 0.018 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 9.601320e-01 | 0.018 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.601320e-01 | 0.018 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.601320e-01 | 0.018 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 9.601320e-01 | 0.018 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 9.602192e-01 | 0.018 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 9.608013e-01 | 0.017 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.608538e-01 | 0.017 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 9.610544e-01 | 0.017 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 9.610544e-01 | 0.017 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.610544e-01 | 0.017 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.610544e-01 | 0.017 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.612200e-01 | 0.017 | 0 | 0 |
| Depurination | R-HSA-73927 | 9.612200e-01 | 0.017 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.612200e-01 | 0.017 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.612200e-01 | 0.017 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.620609e-01 | 0.017 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.637008e-01 | 0.016 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.646076e-01 | 0.016 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.646076e-01 | 0.016 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.647623e-01 | 0.016 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.647623e-01 | 0.016 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.647623e-01 | 0.016 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.647623e-01 | 0.016 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 9.647623e-01 | 0.016 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.652631e-01 | 0.015 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.652631e-01 | 0.015 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.652631e-01 | 0.015 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.652631e-01 | 0.015 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.652750e-01 | 0.015 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.661952e-01 | 0.015 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 9.663997e-01 | 0.015 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.663997e-01 | 0.015 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 9.663997e-01 | 0.015 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.663997e-01 | 0.015 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.685924e-01 | 0.014 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 9.688333e-01 | 0.014 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.688730e-01 | 0.014 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.688730e-01 | 0.014 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 9.689062e-01 | 0.014 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 9.710117e-01 | 0.013 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 9.710117e-01 | 0.013 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.710117e-01 | 0.013 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.710117e-01 | 0.013 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 9.711310e-01 | 0.013 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.711310e-01 | 0.013 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.714529e-01 | 0.013 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.721858e-01 | 0.012 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.721858e-01 | 0.012 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 9.725194e-01 | 0.012 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.725194e-01 | 0.012 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 9.725194e-01 | 0.012 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.725280e-01 | 0.012 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 9.739535e-01 | 0.011 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 9.740700e-01 | 0.011 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.749908e-01 | 0.011 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.749908e-01 | 0.011 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 9.749908e-01 | 0.011 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.749908e-01 | 0.011 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.749908e-01 | 0.011 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.751355e-01 | 0.011 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.754988e-01 | 0.011 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.757515e-01 | 0.011 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.757515e-01 | 0.011 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.761656e-01 | 0.010 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 9.771456e-01 | 0.010 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.777863e-01 | 0.010 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.777863e-01 | 0.010 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 9.777863e-01 | 0.010 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 9.777863e-01 | 0.010 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.784240e-01 | 0.009 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 9.784240e-01 | 0.009 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.784240e-01 | 0.009 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.784240e-01 | 0.009 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.784240e-01 | 0.009 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.784240e-01 | 0.009 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 9.786143e-01 | 0.009 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 9.786143e-01 | 0.009 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.786143e-01 | 0.009 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 9.786143e-01 | 0.009 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 9.788274e-01 | 0.009 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 9.788388e-01 | 0.009 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.789638e-01 | 0.009 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.800050e-01 | 0.009 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.809442e-01 | 0.008 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 9.811484e-01 | 0.008 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.811484e-01 | 0.008 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.811484e-01 | 0.008 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 9.813860e-01 | 0.008 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.813860e-01 | 0.008 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.821528e-01 | 0.008 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.833899e-01 | 0.007 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.833899e-01 | 0.007 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.833899e-01 | 0.007 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 9.833899e-01 | 0.007 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 9.833899e-01 | 0.007 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.836910e-01 | 0.007 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 9.839415e-01 | 0.007 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 9.839415e-01 | 0.007 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.839415e-01 | 0.007 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.839415e-01 | 0.007 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.839415e-01 | 0.007 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 9.839415e-01 | 0.007 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 9.839415e-01 | 0.007 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.841175e-01 | 0.007 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.845751e-01 | 0.007 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 9.847861e-01 | 0.007 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.853714e-01 | 0.006 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.853714e-01 | 0.006 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 9.853714e-01 | 0.006 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.856264e-01 | 0.006 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.856264e-01 | 0.006 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.858202e-01 | 0.006 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.859315e-01 | 0.006 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.861464e-01 | 0.006 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 9.861464e-01 | 0.006 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.861464e-01 | 0.006 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 9.861464e-01 | 0.006 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.869992e-01 | 0.006 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.871221e-01 | 0.006 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.873047e-01 | 0.006 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.873150e-01 | 0.006 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 9.880486e-01 | 0.005 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.880486e-01 | 0.005 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.880486e-01 | 0.005 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.887576e-01 | 0.005 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.887576e-01 | 0.005 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.893761e-01 | 0.005 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.893815e-01 | 0.005 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.896897e-01 | 0.005 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.896897e-01 | 0.005 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.899612e-01 | 0.004 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 9.900321e-01 | 0.004 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.900684e-01 | 0.004 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 9.900684e-01 | 0.004 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.903648e-01 | 0.004 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.904112e-01 | 0.004 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.905845e-01 | 0.004 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.911055e-01 | 0.004 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.911055e-01 | 0.004 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.911196e-01 | 0.004 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.911462e-01 | 0.004 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.911527e-01 | 0.004 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 9.912346e-01 | 0.004 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.916009e-01 | 0.004 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.917759e-01 | 0.004 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.917759e-01 | 0.004 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.917759e-01 | 0.004 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 9.917841e-01 | 0.004 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.918176e-01 | 0.004 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.919269e-01 | 0.004 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 9.921928e-01 | 0.003 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.922964e-01 | 0.003 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.922964e-01 | 0.003 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.923270e-01 | 0.003 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.923270e-01 | 0.003 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.923869e-01 | 0.003 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 9.923869e-01 | 0.003 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.929606e-01 | 0.003 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.932313e-01 | 0.003 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.933808e-01 | 0.003 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 9.933808e-01 | 0.003 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.933808e-01 | 0.003 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 9.933808e-01 | 0.003 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.933808e-01 | 0.003 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.936560e-01 | 0.003 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.936627e-01 | 0.003 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.940548e-01 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.940548e-01 | 0.003 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.940548e-01 | 0.003 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.942899e-01 | 0.002 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.943889e-01 | 0.002 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.948075e-01 | 0.002 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.948548e-01 | 0.002 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.950742e-01 | 0.002 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.951131e-01 | 0.002 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.951723e-01 | 0.002 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.953695e-01 | 0.002 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.954179e-01 | 0.002 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.957509e-01 | 0.002 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 9.957509e-01 | 0.002 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.958346e-01 | 0.002 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.958492e-01 | 0.002 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.958585e-01 | 0.002 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.959792e-01 | 0.002 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 9.961137e-01 | 0.002 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.961550e-01 | 0.002 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.961550e-01 | 0.002 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.962011e-01 | 0.002 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.963828e-01 | 0.002 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.964728e-01 | 0.002 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.965339e-01 | 0.002 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 9.965575e-01 | 0.001 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.968008e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.968381e-01 | 0.001 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.969067e-01 | 0.001 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.969067e-01 | 0.001 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.969067e-01 | 0.001 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.969794e-01 | 0.001 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.970412e-01 | 0.001 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.972725e-01 | 0.001 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.972725e-01 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.972880e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.972880e-01 | 0.001 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.973243e-01 | 0.001 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.973243e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.973388e-01 | 0.001 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.973575e-01 | 0.001 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.974026e-01 | 0.001 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.975996e-01 | 0.001 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.976473e-01 | 0.001 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.976473e-01 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.979170e-01 | 0.001 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.979531e-01 | 0.001 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.979705e-01 | 0.001 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.979705e-01 | 0.001 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.981440e-01 | 0.001 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.983107e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.983124e-01 | 0.001 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.983581e-01 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.983758e-01 | 0.001 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 9.984018e-01 | 0.001 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.984018e-01 | 0.001 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.984900e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.984900e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.985512e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.986752e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.986752e-01 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.986936e-01 | 0.001 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.986975e-01 | 0.001 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.988674e-01 | 0.000 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.988765e-01 | 0.000 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.988883e-01 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.989626e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.989977e-01 | 0.000 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.990309e-01 | 0.000 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.990618e-01 | 0.000 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.991641e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.991792e-01 | 0.000 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.991890e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.993100e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.993100e-01 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.993519e-01 | 0.000 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.993722e-01 | 0.000 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.993781e-01 | 0.000 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.994349e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.994628e-01 | 0.000 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.994636e-01 | 0.000 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 9.994636e-01 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.995202e-01 | 0.000 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.995374e-01 | 0.000 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.995374e-01 | 0.000 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.995374e-01 | 0.000 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.995601e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.995807e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.995821e-01 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.996010e-01 | 0.000 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.996010e-01 | 0.000 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.996558e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.997139e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.997139e-01 | 0.000 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.997152e-01 | 0.000 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.997152e-01 | 0.000 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.997219e-01 | 0.000 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.997440e-01 | 0.000 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.997440e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.997468e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.997792e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.998138e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.998138e-01 | 0.000 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.998226e-01 | 0.000 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 9.998259e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.998357e-01 | 0.000 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.998548e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.998667e-01 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.998778e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.999091e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.999091e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.999212e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999250e-01 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.999375e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999459e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.999497e-01 | 0.000 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.999541e-01 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.999548e-01 | 0.000 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.999566e-01 | 0.000 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.999606e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.999793e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999799e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999809e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999831e-01 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.999842e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.999846e-01 | 0.000 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.999853e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.999880e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999896e-01 | 0.000 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.999896e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.999909e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999915e-01 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.999925e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999927e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999950e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999951e-01 | 0.000 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.999955e-01 | 0.000 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.999957e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999970e-01 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.999974e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999977e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.999981e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999990e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.999992e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999992e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999993e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999995e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.999998e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999999e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999999e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999999e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.999999e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000e+00 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 1.000000e+00 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 1.000000e+00 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.000000e+00 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.000000e+00 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cellular response to heat stress | R-HSA-3371556 | 3.330669e-16 | 15.477 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.543210e-14 | 13.812 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.131628e-14 | 13.671 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 8.579804e-13 | 12.067 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.420508e-12 | 11.616 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 4.238054e-12 | 11.373 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.084277e-11 | 10.965 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 1.239753e-11 | 10.907 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.362577e-11 | 10.866 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.710798e-11 | 10.431 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.264727e-10 | 9.898 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 2.076691e-10 | 9.683 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 5.189530e-10 | 9.285 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 3.635691e-09 | 8.439 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.084970e-09 | 8.389 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 4.375887e-09 | 8.359 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.614572e-09 | 8.336 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 5.053237e-09 | 8.296 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 8.778599e-09 | 8.057 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.312087e-09 | 8.031 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.341472e-08 | 7.872 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.688202e-08 | 7.773 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.622436e-08 | 7.441 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 6.073268e-08 | 7.217 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 7.308408e-08 | 7.136 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 7.770609e-08 | 7.110 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 9.286511e-08 | 7.032 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.061747e-07 | 6.974 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.142743e-07 | 6.942 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.215166e-07 | 6.915 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.898250e-07 | 6.722 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.316609e-07 | 6.635 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 2.327249e-07 | 6.633 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 2.516279e-07 | 6.599 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 3.012038e-07 | 6.521 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 3.179957e-07 | 6.498 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 3.418216e-07 | 6.466 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 3.387017e-07 | 6.470 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.083243e-07 | 6.389 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.532863e-07 | 6.344 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 7.271645e-07 | 6.138 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.815255e-07 | 6.107 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.904222e-07 | 6.004 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 9.991939e-07 | 6.000 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.088760e-06 | 5.963 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.139457e-06 | 5.943 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.206790e-06 | 5.918 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.209924e-06 | 5.917 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.313743e-06 | 5.881 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.320299e-06 | 5.879 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.589701e-06 | 5.799 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.646963e-06 | 5.783 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.688096e-06 | 5.773 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 2.138008e-06 | 5.670 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.474869e-06 | 5.606 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.600986e-06 | 5.585 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 2.639631e-06 | 5.578 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 2.975267e-06 | 5.526 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 2.976011e-06 | 5.526 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 3.710510e-06 | 5.431 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 3.904183e-06 | 5.408 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.456704e-06 | 5.351 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.456704e-06 | 5.351 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 5.006805e-06 | 5.300 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.829705e-06 | 5.316 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 5.498751e-06 | 5.260 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.616339e-06 | 5.251 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 6.150180e-06 | 5.211 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 6.013985e-06 | 5.221 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 6.318469e-06 | 5.199 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 6.817121e-06 | 5.166 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 9.746288e-06 | 5.011 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.394743e-05 | 4.856 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.370632e-05 | 4.863 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.613514e-05 | 4.792 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 1.613514e-05 | 4.792 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.762427e-05 | 4.754 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.905777e-05 | 4.720 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.905777e-05 | 4.720 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.148704e-05 | 4.668 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 2.247974e-05 | 4.648 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 2.728822e-05 | 4.564 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.955152e-05 | 4.529 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.265165e-05 | 4.486 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 3.445607e-05 | 4.463 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.445607e-05 | 4.463 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.710309e-05 | 4.431 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.743995e-05 | 4.427 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.057338e-05 | 4.392 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 4.564128e-05 | 4.341 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.581235e-05 | 4.339 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 4.715262e-05 | 4.326 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.903158e-05 | 4.310 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 4.903453e-05 | 4.309 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 4.903453e-05 | 4.309 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 5.002454e-05 | 4.301 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 5.617530e-05 | 4.250 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 6.000979e-05 | 4.222 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.959258e-05 | 4.225 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 6.484207e-05 | 4.188 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 6.604715e-05 | 4.180 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 6.604715e-05 | 4.180 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 6.604715e-05 | 4.180 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 7.338281e-05 | 4.134 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 7.708528e-05 | 4.113 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 7.922622e-05 | 4.101 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 7.947499e-05 | 4.100 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 7.947499e-05 | 4.100 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.038318e-05 | 4.095 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.005204e-04 | 3.998 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.216700e-04 | 3.915 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.216700e-04 | 3.915 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.216700e-04 | 3.915 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.216700e-04 | 3.915 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.207123e-04 | 3.918 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.175592e-04 | 3.930 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.266619e-04 | 3.897 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.292162e-04 | 3.889 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 1.354173e-04 | 3.868 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 1.472212e-04 | 3.832 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.674599e-04 | 3.776 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.632398e-04 | 3.787 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.712477e-04 | 3.766 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.795458e-04 | 3.746 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.833186e-04 | 3.737 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.911234e-04 | 3.719 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.918885e-04 | 3.717 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.920054e-04 | 3.717 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.017659e-04 | 3.695 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.047096e-04 | 3.689 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 2.344271e-04 | 3.630 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.259676e-04 | 3.646 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.462515e-04 | 3.609 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 2.574892e-04 | 3.589 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 2.656700e-04 | 3.576 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.737069e-04 | 3.563 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 2.821118e-04 | 3.550 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 2.838585e-04 | 3.547 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.069831e-04 | 3.513 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 3.930087e-04 | 3.406 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.953600e-04 | 3.403 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 3.599851e-04 | 3.444 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.662199e-04 | 3.436 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 3.784465e-04 | 3.422 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.597095e-04 | 3.444 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.031011e-04 | 3.395 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.101895e-04 | 3.387 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 4.159257e-04 | 3.381 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 4.308155e-04 | 3.366 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 4.451495e-04 | 3.351 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.837146e-04 | 3.315 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 4.853142e-04 | 3.314 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 5.282610e-04 | 3.277 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 5.287015e-04 | 3.277 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 5.375113e-04 | 3.270 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.676482e-04 | 3.246 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 5.778350e-04 | 3.238 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 6.872610e-04 | 3.163 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 7.127422e-04 | 3.147 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 6.438759e-04 | 3.191 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 6.872610e-04 | 3.163 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 6.822787e-04 | 3.166 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 7.794934e-04 | 3.108 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.798129e-04 | 3.108 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.235010e-04 | 3.084 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 8.235010e-04 | 3.084 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 8.365812e-04 | 3.077 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 8.365812e-04 | 3.077 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 8.579922e-04 | 3.067 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 8.670507e-04 | 3.062 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 8.670507e-04 | 3.062 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 8.670507e-04 | 3.062 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 8.818870e-04 | 3.055 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 9.077391e-04 | 3.042 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 9.616042e-04 | 3.017 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 9.783883e-04 | 3.009 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 9.783883e-04 | 3.009 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 1.020961e-03 | 2.991 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.028109e-03 | 2.988 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.115176e-03 | 2.953 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.044442e-03 | 2.981 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.157706e-03 | 2.936 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.105366e-03 | 2.956 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.119674e-03 | 2.951 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.185427e-03 | 2.926 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 1.275490e-03 | 2.894 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 1.275490e-03 | 2.894 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.278246e-03 | 2.893 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.296215e-03 | 2.887 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.296215e-03 | 2.887 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 1.345020e-03 | 2.871 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.418367e-03 | 2.848 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.418367e-03 | 2.848 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.477142e-03 | 2.831 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.532942e-03 | 2.814 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.545507e-03 | 2.811 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.730470e-03 | 2.762 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 1.751765e-03 | 2.757 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.788191e-03 | 2.748 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.842645e-03 | 2.735 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.902121e-03 | 2.721 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 2.038004e-03 | 2.691 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 2.038004e-03 | 2.691 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.045746e-03 | 2.689 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 2.080296e-03 | 2.682 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 2.080296e-03 | 2.682 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 2.257849e-03 | 2.646 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 2.212113e-03 | 2.655 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 2.456741e-03 | 2.610 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.345423e-03 | 2.630 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.522690e-03 | 2.598 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.599628e-03 | 2.585 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.739239e-03 | 2.562 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 2.842860e-03 | 2.546 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.916963e-03 | 2.535 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.010876e-03 | 2.521 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 3.129260e-03 | 2.505 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.159638e-03 | 2.500 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 3.456408e-03 | 2.461 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.559101e-03 | 2.449 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.593066e-03 | 2.445 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 3.651131e-03 | 2.438 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.693453e-03 | 2.433 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 3.693453e-03 | 2.433 | 0 | 0 |
| Kinesins | R-HSA-983189 | 3.712747e-03 | 2.430 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 3.714240e-03 | 2.430 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.826941e-03 | 2.417 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.860271e-03 | 2.413 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.949198e-03 | 2.403 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.949198e-03 | 2.403 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 4.101903e-03 | 2.387 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 4.388725e-03 | 2.358 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 4.388725e-03 | 2.358 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 4.388725e-03 | 2.358 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 5.020847e-03 | 2.299 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 4.609548e-03 | 2.336 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 4.433238e-03 | 2.353 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.993385e-03 | 2.302 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 5.123438e-03 | 2.290 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 5.125524e-03 | 2.290 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.626573e-03 | 2.335 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 4.865545e-03 | 2.313 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 4.940110e-03 | 2.306 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 5.159653e-03 | 2.287 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 5.159653e-03 | 2.287 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.347230e-03 | 2.272 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 5.539584e-03 | 2.257 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 5.825161e-03 | 2.235 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 5.880048e-03 | 2.231 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.880048e-03 | 2.231 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 6.027659e-03 | 2.220 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 6.117346e-03 | 2.213 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 6.117346e-03 | 2.213 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 6.117346e-03 | 2.213 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 6.571280e-03 | 2.182 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 6.571995e-03 | 2.182 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 6.571995e-03 | 2.182 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 6.682456e-03 | 2.175 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 6.803553e-03 | 2.167 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 6.813458e-03 | 2.167 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 6.986456e-03 | 2.156 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 7.053759e-03 | 2.152 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 7.053759e-03 | 2.152 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 7.056169e-03 | 2.151 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 7.056169e-03 | 2.151 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 7.151537e-03 | 2.146 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 7.250111e-03 | 2.140 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 7.330861e-03 | 2.135 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 7.474935e-03 | 2.126 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 7.485940e-03 | 2.126 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 7.485940e-03 | 2.126 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 7.485940e-03 | 2.126 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 7.534423e-03 | 2.123 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 7.811095e-03 | 2.107 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 8.000149e-03 | 2.097 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 8.540038e-03 | 2.069 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 8.547130e-03 | 2.068 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 8.668370e-03 | 2.062 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.049848e-02 | 1.979 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 9.076599e-03 | 2.042 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.623512e-03 | 2.017 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.514911e-03 | 2.022 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 9.756382e-03 | 2.011 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.049848e-02 | 1.979 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 9.733789e-03 | 2.012 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 9.076599e-03 | 2.042 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.509172e-03 | 2.022 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 9.254224e-03 | 2.034 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 9.448572e-03 | 2.025 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 1.091051e-02 | 1.962 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 1.091051e-02 | 1.962 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.122628e-02 | 1.950 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.144401e-02 | 1.941 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.144401e-02 | 1.941 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.163878e-02 | 1.934 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.169952e-02 | 1.932 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.172756e-02 | 1.931 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.172756e-02 | 1.931 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 1.213959e-02 | 1.916 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.261875e-02 | 1.899 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 1.300890e-02 | 1.886 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.316832e-02 | 1.880 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.367383e-02 | 1.864 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.367383e-02 | 1.864 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.367383e-02 | 1.864 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.367383e-02 | 1.864 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 1.410124e-02 | 1.851 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.419812e-02 | 1.848 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.436613e-02 | 1.843 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.436613e-02 | 1.843 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.456528e-02 | 1.837 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.456528e-02 | 1.837 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.535213e-02 | 1.814 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.539288e-02 | 1.813 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.601665e-02 | 1.795 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.638818e-02 | 1.785 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 1.718663e-02 | 1.765 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.718663e-02 | 1.765 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.718663e-02 | 1.765 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 1.728240e-02 | 1.762 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.758047e-02 | 1.755 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 1.758047e-02 | 1.755 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.785934e-02 | 1.748 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 1.822338e-02 | 1.739 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.844085e-02 | 1.734 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.844085e-02 | 1.734 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 1.844085e-02 | 1.734 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.845397e-02 | 1.734 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.903262e-02 | 1.721 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.021472e-02 | 1.694 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.021472e-02 | 1.694 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.021472e-02 | 1.694 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.021472e-02 | 1.694 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 2.021472e-02 | 1.694 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.021472e-02 | 1.694 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.021472e-02 | 1.694 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 2.424244e-02 | 1.615 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 2.424244e-02 | 1.615 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.424244e-02 | 1.615 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 2.424244e-02 | 1.615 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.296779e-02 | 1.639 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.296779e-02 | 1.639 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 2.061105e-02 | 1.686 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 2.061105e-02 | 1.686 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 2.061105e-02 | 1.686 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.119135e-02 | 1.674 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 2.424244e-02 | 1.615 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 2.241952e-02 | 1.649 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 2.351892e-02 | 1.629 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 2.051133e-02 | 1.688 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.051133e-02 | 1.688 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 2.231630e-02 | 1.651 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 2.231630e-02 | 1.651 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 2.462365e-02 | 1.609 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 2.473198e-02 | 1.607 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 2.473198e-02 | 1.607 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 2.474105e-02 | 1.607 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.530326e-02 | 1.597 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.532515e-02 | 1.596 | 0 | 0 |
| Depurination | R-HSA-73927 | 2.683239e-02 | 1.571 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 2.683449e-02 | 1.571 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.727305e-02 | 1.564 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 2.761016e-02 | 1.559 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 2.785770e-02 | 1.555 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.808945e-02 | 1.551 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.818649e-02 | 1.550 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 2.818649e-02 | 1.550 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.818649e-02 | 1.550 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.818877e-02 | 1.550 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 2.843196e-02 | 1.546 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 2.843196e-02 | 1.546 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.848577e-02 | 1.545 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.905893e-02 | 1.537 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.913077e-02 | 1.536 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.913077e-02 | 1.536 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.932111e-02 | 1.533 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 3.117950e-02 | 1.506 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 3.134608e-02 | 1.504 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.134608e-02 | 1.504 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 3.149629e-02 | 1.502 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 3.212348e-02 | 1.493 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 3.212348e-02 | 1.493 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 3.227602e-02 | 1.491 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.267746e-02 | 1.486 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.267746e-02 | 1.486 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 3.269031e-02 | 1.486 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 3.293618e-02 | 1.482 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.316203e-02 | 1.479 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.316203e-02 | 1.479 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 3.347728e-02 | 1.475 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 3.378158e-02 | 1.471 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 3.378158e-02 | 1.471 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 3.458819e-02 | 1.461 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 3.654814e-02 | 1.437 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.656274e-02 | 1.437 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 3.657750e-02 | 1.437 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.680153e-02 | 1.434 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 3.680153e-02 | 1.434 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.736181e-02 | 1.428 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 3.842764e-02 | 1.415 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.874914e-02 | 1.412 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.897078e-02 | 1.409 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.897078e-02 | 1.409 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 3.897078e-02 | 1.409 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 3.897078e-02 | 1.409 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 3.897078e-02 | 1.409 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 3.987969e-02 | 1.399 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 3.987969e-02 | 1.399 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 4.034987e-02 | 1.394 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 4.045731e-02 | 1.393 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 4.126302e-02 | 1.384 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 4.126302e-02 | 1.384 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 4.171791e-02 | 1.380 | 0 | 0 |
| S Phase | R-HSA-69242 | 4.206081e-02 | 1.376 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 4.239651e-02 | 1.373 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 4.239651e-02 | 1.373 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 4.239651e-02 | 1.373 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 5.409303e-02 | 1.267 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 5.409303e-02 | 1.267 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 5.409303e-02 | 1.267 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 5.657263e-02 | 1.247 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 4.453817e-02 | 1.351 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 5.203054e-02 | 1.284 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.567889e-02 | 1.254 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 5.485457e-02 | 1.261 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.604334e-02 | 1.337 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.035562e-02 | 1.298 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 4.384200e-02 | 1.358 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 4.763221e-02 | 1.322 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 5.208721e-02 | 1.283 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 5.208721e-02 | 1.283 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 5.222077e-02 | 1.282 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 5.283398e-02 | 1.277 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.691693e-02 | 1.329 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 4.830646e-02 | 1.316 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 5.386797e-02 | 1.269 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 4.432379e-02 | 1.353 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 5.666193e-02 | 1.247 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 5.052761e-02 | 1.296 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.650492e-02 | 1.333 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 5.357787e-02 | 1.271 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.910386e-02 | 1.309 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.398948e-02 | 1.268 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.453817e-02 | 1.351 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 5.700669e-02 | 1.244 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.700669e-02 | 1.244 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 5.711771e-02 | 1.243 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 5.717077e-02 | 1.243 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 5.733019e-02 | 1.242 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.734357e-02 | 1.242 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 5.734357e-02 | 1.242 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 5.865642e-02 | 1.232 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 5.876703e-02 | 1.231 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 5.905364e-02 | 1.229 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 5.920677e-02 | 1.228 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 5.957487e-02 | 1.225 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 5.969021e-02 | 1.224 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 6.150325e-02 | 1.211 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 6.174173e-02 | 1.209 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 6.337517e-02 | 1.198 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.430875e-02 | 1.192 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 6.451532e-02 | 1.190 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 6.451532e-02 | 1.190 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 6.479677e-02 | 1.188 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.534144e-02 | 1.185 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.563722e-02 | 1.183 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 6.563722e-02 | 1.183 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 6.563722e-02 | 1.183 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 6.810551e-02 | 1.167 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 6.810551e-02 | 1.167 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 6.810551e-02 | 1.167 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.810551e-02 | 1.167 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 7.011330e-02 | 1.154 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 7.030374e-02 | 1.153 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 7.030374e-02 | 1.153 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 7.030374e-02 | 1.153 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 7.030374e-02 | 1.153 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 7.030374e-02 | 1.153 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 7.030374e-02 | 1.153 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 7.145817e-02 | 1.146 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 7.223472e-02 | 1.141 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.223472e-02 | 1.141 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 7.223472e-02 | 1.141 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 7.248281e-02 | 1.140 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 7.514995e-02 | 1.124 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 7.516011e-02 | 1.124 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 7.516011e-02 | 1.124 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 7.516011e-02 | 1.124 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.516011e-02 | 1.124 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 7.550115e-02 | 1.122 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 7.550115e-02 | 1.122 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 7.696857e-02 | 1.114 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.792857e-02 | 1.108 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.912816e-02 | 1.102 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.947789e-02 | 1.100 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 8.163560e-02 | 1.088 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 8.848508e-02 | 1.053 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 8.928367e-02 | 1.049 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 9.272502e-02 | 1.033 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 9.272502e-02 | 1.033 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 9.272502e-02 | 1.033 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 9.272502e-02 | 1.033 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 9.272502e-02 | 1.033 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 9.412615e-02 | 1.026 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.023685e-01 | 0.990 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 1.023685e-01 | 0.990 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 1.023685e-01 | 0.990 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 1.023685e-01 | 0.990 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.025331e-01 | 0.989 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.025331e-01 | 0.989 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.379083e-01 | 0.860 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 1.379083e-01 | 0.860 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 1.379083e-01 | 0.860 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 9.551734e-02 | 1.020 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 9.551734e-02 | 1.020 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.178431e-01 | 0.929 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 1.178431e-01 | 0.929 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 1.178431e-01 | 0.929 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 1.178431e-01 | 0.929 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 9.730704e-02 | 1.012 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 9.730704e-02 | 1.012 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 9.730704e-02 | 1.012 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 1.418858e-01 | 0.848 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.418858e-01 | 0.848 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 1.418858e-01 | 0.848 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.418858e-01 | 0.848 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.144387e-01 | 0.941 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 1.327878e-01 | 0.877 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.327878e-01 | 0.877 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.065278e-01 | 0.973 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 1.212736e-01 | 0.916 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.212736e-01 | 0.916 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 1.098001e-01 | 0.959 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 1.369131e-01 | 0.864 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 1.369131e-01 | 0.864 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 9.907410e-02 | 1.004 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.297145e-01 | 0.887 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 1.410875e-01 | 0.851 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 1.410875e-01 | 0.851 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 1.410875e-01 | 0.851 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.410875e-01 | 0.851 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.310676e-01 | 0.883 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 9.702646e-02 | 1.013 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 1.153663e-01 | 0.938 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 1.153663e-01 | 0.938 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 9.907410e-02 | 1.004 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 1.369131e-01 | 0.864 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.215120e-01 | 0.915 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 1.065278e-01 | 0.973 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 1.252231e-01 | 0.902 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.379083e-01 | 0.860 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 1.069159e-01 | 0.971 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 1.379083e-01 | 0.860 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.363951e-01 | 0.865 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.178431e-01 | 0.929 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.425542e-01 | 0.846 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.297145e-01 | 0.887 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.025331e-01 | 0.989 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.298423e-01 | 0.887 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 1.327878e-01 | 0.877 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 9.863836e-02 | 1.006 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.212736e-01 | 0.916 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 1.418858e-01 | 0.848 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 1.380789e-01 | 0.860 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.025331e-01 | 0.989 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.379083e-01 | 0.860 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.418858e-01 | 0.848 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.418858e-01 | 0.848 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.315017e-01 | 0.881 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 1.011225e-01 | 0.995 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.327878e-01 | 0.877 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 1.418858e-01 | 0.848 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.418858e-01 | 0.848 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.153663e-01 | 0.938 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 9.551734e-02 | 1.020 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 9.551734e-02 | 1.020 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.164178e-01 | 0.934 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 1.375958e-01 | 0.861 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.004669e-01 | 0.998 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.269619e-01 | 0.896 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 1.212736e-01 | 0.916 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 1.300958e-01 | 0.886 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.465792e-01 | 0.834 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.507254e-01 | 0.822 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 1.507254e-01 | 0.822 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.516078e-01 | 0.819 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.522490e-01 | 0.817 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 1.522490e-01 | 0.817 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.522490e-01 | 0.817 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 1.522490e-01 | 0.817 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 1.529380e-01 | 0.815 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.533901e-01 | 0.814 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.533901e-01 | 0.814 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.533901e-01 | 0.814 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.535397e-01 | 0.814 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.542750e-01 | 0.812 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 1.545272e-01 | 0.811 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 1.595553e-01 | 0.797 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.602339e-01 | 0.795 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.618009e-01 | 0.791 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 1.652477e-01 | 0.782 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 1.652477e-01 | 0.782 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 1.652477e-01 | 0.782 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.652477e-01 | 0.782 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.673872e-01 | 0.776 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.673872e-01 | 0.776 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.673872e-01 | 0.776 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.673872e-01 | 0.776 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 1.673872e-01 | 0.776 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.706428e-01 | 0.768 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.706428e-01 | 0.768 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.710620e-01 | 0.767 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.732992e-01 | 0.761 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.752094e-01 | 0.756 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.754483e-01 | 0.756 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.754483e-01 | 0.756 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 1.754483e-01 | 0.756 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 1.754483e-01 | 0.756 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 1.754483e-01 | 0.756 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 1.754483e-01 | 0.756 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 1.754483e-01 | 0.756 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 1.754483e-01 | 0.756 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 1.754483e-01 | 0.756 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 1.754483e-01 | 0.756 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.754483e-01 | 0.756 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 1.754483e-01 | 0.756 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 1.758386e-01 | 0.755 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 1.779963e-01 | 0.750 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.793012e-01 | 0.746 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.797366e-01 | 0.745 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.864184e-01 | 0.730 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 1.875418e-01 | 0.727 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.875418e-01 | 0.727 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 1.886050e-01 | 0.724 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 1.886050e-01 | 0.724 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 1.886050e-01 | 0.724 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 1.911617e-01 | 0.719 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.911617e-01 | 0.719 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 1.911617e-01 | 0.719 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 1.929444e-01 | 0.715 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 1.931929e-01 | 0.714 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.940505e-01 | 0.712 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 1.940505e-01 | 0.712 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 1.940505e-01 | 0.712 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 1.940505e-01 | 0.712 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.940907e-01 | 0.712 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.940907e-01 | 0.712 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.942631e-01 | 0.712 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 1.942631e-01 | 0.712 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.942631e-01 | 0.712 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 1.942631e-01 | 0.712 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 1.942631e-01 | 0.712 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.942631e-01 | 0.712 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.942631e-01 | 0.712 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.973879e-01 | 0.705 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 1.973879e-01 | 0.705 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.973879e-01 | 0.705 | 0 | 0 |
| Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4), distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA) | R-HSA-5619050 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 2.767549e-01 | 0.558 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.767549e-01 | 0.558 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 2.767549e-01 | 0.558 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 2.767549e-01 | 0.558 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective APRT disrupts adenine salvage | R-HSA-9734195 | 2.767549e-01 | 0.558 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 2.767549e-01 | 0.558 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 2.767549e-01 | 0.558 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 2.143399e-01 | 0.669 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.143399e-01 | 0.669 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.508055e-01 | 0.455 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 3.508055e-01 | 0.455 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 3.508055e-01 | 0.455 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.508055e-01 | 0.455 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.508055e-01 | 0.455 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.508055e-01 | 0.455 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.508055e-01 | 0.455 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 3.508055e-01 | 0.455 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 3.508055e-01 | 0.455 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 3.508055e-01 | 0.455 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.539135e-01 | 0.595 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 2.217467e-01 | 0.654 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 2.217467e-01 | 0.654 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 2.217467e-01 | 0.654 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 2.217467e-01 | 0.654 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.936222e-01 | 0.532 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 2.936222e-01 | 0.532 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 2.936222e-01 | 0.532 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 2.936222e-01 | 0.532 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 2.936222e-01 | 0.532 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 2.501172e-01 | 0.602 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 2.501172e-01 | 0.602 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 2.501172e-01 | 0.602 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 2.501172e-01 | 0.602 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 2.501172e-01 | 0.602 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 3.330238e-01 | 0.478 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.789787e-01 | 0.554 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.388928e-01 | 0.622 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.388928e-01 | 0.622 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.388928e-01 | 0.622 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 3.081240e-01 | 0.511 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 3.081240e-01 | 0.511 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.717654e-01 | 0.430 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 3.373640e-01 | 0.472 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 3.373640e-01 | 0.472 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 2.486134e-01 | 0.604 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 3.097637e-01 | 0.509 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 2.186466e-01 | 0.660 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.056655e-01 | 0.687 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 3.665274e-01 | 0.436 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.329145e-01 | 0.633 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 3.338937e-01 | 0.476 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.186050e-01 | 0.660 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.072638e-01 | 0.512 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.072638e-01 | 0.512 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.161743e-01 | 0.665 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 3.281724e-01 | 0.484 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 3.281724e-01 | 0.484 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.954615e-01 | 0.403 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 3.954615e-01 | 0.403 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.591670e-01 | 0.586 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.217056e-01 | 0.493 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 3.703249e-01 | 0.431 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 3.241102e-01 | 0.489 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 2.562556e-01 | 0.591 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 3.399672e-01 | 0.469 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.399672e-01 | 0.469 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 3.666218e-01 | 0.436 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 3.839760e-01 | 0.416 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 3.719791e-01 | 0.429 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 3.880765e-01 | 0.411 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 3.873953e-01 | 0.412 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.661264e-01 | 0.575 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 2.486134e-01 | 0.604 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 2.661264e-01 | 0.575 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 3.081240e-01 | 0.511 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 2.263771e-01 | 0.645 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.425279e-01 | 0.465 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.425279e-01 | 0.465 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 2.877102e-01 | 0.541 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.605881e-01 | 0.584 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.581012e-01 | 0.446 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 3.954615e-01 | 0.403 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 3.522404e-01 | 0.453 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.936222e-01 | 0.532 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 3.717654e-01 | 0.430 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 2.486134e-01 | 0.604 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.518247e-01 | 0.599 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 2.061944e-01 | 0.686 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 3.665274e-01 | 0.436 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 3.665274e-01 | 0.436 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 2.226819e-01 | 0.652 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.217467e-01 | 0.654 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.217467e-01 | 0.654 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 2.501172e-01 | 0.602 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 3.373640e-01 | 0.472 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.176884e-01 | 0.662 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 3.822902e-01 | 0.418 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 3.703249e-01 | 0.431 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.421067e-01 | 0.466 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 2.661264e-01 | 0.575 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 3.731344e-01 | 0.428 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 3.666877e-01 | 0.436 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 3.282097e-01 | 0.484 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 3.666877e-01 | 0.436 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 2.501172e-01 | 0.602 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 2.417044e-01 | 0.617 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.097637e-01 | 0.509 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 2.474965e-01 | 0.606 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 2.070165e-01 | 0.684 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 2.321114e-01 | 0.634 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 3.710989e-01 | 0.431 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 2.070165e-01 | 0.684 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 2.070165e-01 | 0.684 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 3.369205e-01 | 0.472 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 2.015994e-01 | 0.696 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 2.143399e-01 | 0.669 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.161521e-01 | 0.665 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.330238e-01 | 0.478 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 3.330238e-01 | 0.478 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 3.717654e-01 | 0.430 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 3.285395e-01 | 0.483 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 3.281724e-01 | 0.484 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.486134e-01 | 0.604 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 2.479264e-01 | 0.606 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 2.501172e-01 | 0.602 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 2.789787e-01 | 0.554 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 3.665274e-01 | 0.436 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 2.858139e-01 | 0.544 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.150366e-01 | 0.502 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 2.143399e-01 | 0.669 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 2.143399e-01 | 0.669 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 2.858139e-01 | 0.544 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.641477e-01 | 0.578 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 2.562662e-01 | 0.591 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.719791e-01 | 0.429 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.493230e-01 | 0.457 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 2.539135e-01 | 0.595 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 2.022430e-01 | 0.694 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 3.954615e-01 | 0.403 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.281724e-01 | 0.484 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 3.880765e-01 | 0.411 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 2.918581e-01 | 0.535 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.621525e-01 | 0.581 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.665987e-01 | 0.574 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 3.373640e-01 | 0.472 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 2.090046e-01 | 0.680 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 2.767549e-01 | 0.558 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 2.767549e-01 | 0.558 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.767549e-01 | 0.558 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 2.767549e-01 | 0.558 | 0 | 0 |
| Proton/oligopeptide cotransporters | R-HSA-427975 | 2.143399e-01 | 0.669 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.508055e-01 | 0.455 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.508055e-01 | 0.455 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 2.936222e-01 | 0.532 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 3.330238e-01 | 0.478 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.388928e-01 | 0.622 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 2.460415e-01 | 0.609 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 3.072638e-01 | 0.512 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.977212e-01 | 0.526 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 3.934942e-01 | 0.405 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 2.794694e-01 | 0.554 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 2.501172e-01 | 0.602 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 2.427176e-01 | 0.615 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 2.427176e-01 | 0.615 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.072071e-01 | 0.684 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 3.683222e-01 | 0.434 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 3.717654e-01 | 0.430 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.210976e-01 | 0.655 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 2.300733e-01 | 0.638 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 2.936222e-01 | 0.532 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 2.789787e-01 | 0.554 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 2.595671e-01 | 0.586 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 2.556034e-01 | 0.592 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.581012e-01 | 0.446 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 2.767549e-01 | 0.558 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.539135e-01 | 0.595 | 0 | 0 |
| SLC-mediated transport of oligopeptides | R-HSA-9959399 | 2.936222e-01 | 0.532 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 3.717654e-01 | 0.430 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.717654e-01 | 0.430 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 2.328863e-01 | 0.633 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 3.338937e-01 | 0.476 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 3.150366e-01 | 0.502 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 2.936222e-01 | 0.532 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 3.822902e-01 | 0.418 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 3.493230e-01 | 0.457 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 3.880765e-01 | 0.411 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.161521e-01 | 0.665 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 3.717654e-01 | 0.430 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 3.665274e-01 | 0.436 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 3.954615e-01 | 0.403 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 3.783542e-01 | 0.422 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 3.666218e-01 | 0.436 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.321157e-01 | 0.479 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 3.306687e-01 | 0.481 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 2.143399e-01 | 0.669 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 3.717654e-01 | 0.430 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.717654e-01 | 0.430 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.388928e-01 | 0.622 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 2.095914e-01 | 0.679 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 3.717654e-01 | 0.430 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 3.973281e-01 | 0.401 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 3.973281e-01 | 0.401 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 3.973281e-01 | 0.401 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 3.973281e-01 | 0.401 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 3.973281e-01 | 0.401 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.973281e-01 | 0.401 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.977928e-01 | 0.400 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 3.997420e-01 | 0.398 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 3.997420e-01 | 0.398 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 4.013505e-01 | 0.396 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 4.063714e-01 | 0.391 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.063714e-01 | 0.391 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 4.095692e-01 | 0.388 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.095692e-01 | 0.388 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 4.095692e-01 | 0.388 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 4.095692e-01 | 0.388 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 4.095692e-01 | 0.388 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 4.095692e-01 | 0.388 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 4.095692e-01 | 0.388 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.095692e-01 | 0.388 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.095692e-01 | 0.388 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 4.095692e-01 | 0.388 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.095692e-01 | 0.388 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.095692e-01 | 0.388 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 4.107227e-01 | 0.386 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 4.124968e-01 | 0.385 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 4.124968e-01 | 0.385 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 4.155183e-01 | 0.381 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 4.162728e-01 | 0.381 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 4.172782e-01 | 0.380 | 0 | 0 |
| Defective HPRT1 disrupts guanine and hypoxanthine salvage | R-HSA-9734281 | 4.172782e-01 | 0.380 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.172782e-01 | 0.380 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.172782e-01 | 0.380 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.172782e-01 | 0.380 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 4.172782e-01 | 0.380 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.172782e-01 | 0.380 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.172782e-01 | 0.380 | 0 | 0 |
| The NLRP1 inflammasome | R-HSA-844455 | 4.172782e-01 | 0.380 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 4.187114e-01 | 0.378 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 4.240314e-01 | 0.373 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 4.240314e-01 | 0.373 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 4.240314e-01 | 0.373 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 4.240314e-01 | 0.373 | 0 | 0 |
| Immune System | R-HSA-168256 | 4.250880e-01 | 0.372 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 4.302625e-01 | 0.366 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 4.302625e-01 | 0.366 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 4.302625e-01 | 0.366 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 4.323285e-01 | 0.364 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 4.334421e-01 | 0.363 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 4.334421e-01 | 0.363 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 4.349516e-01 | 0.362 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 4.350735e-01 | 0.361 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 4.359343e-01 | 0.361 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.452019e-01 | 0.351 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 4.462211e-01 | 0.350 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.462211e-01 | 0.350 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.462211e-01 | 0.350 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.462211e-01 | 0.350 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 4.462211e-01 | 0.350 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 4.462211e-01 | 0.350 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 4.462211e-01 | 0.350 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 4.521195e-01 | 0.345 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 4.521195e-01 | 0.345 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 4.521195e-01 | 0.345 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 4.521195e-01 | 0.345 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 4.521195e-01 | 0.345 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 4.538885e-01 | 0.343 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.538885e-01 | 0.343 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 4.538885e-01 | 0.343 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 4.539087e-01 | 0.343 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 4.542217e-01 | 0.343 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 4.542217e-01 | 0.343 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 4.542217e-01 | 0.343 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 4.542217e-01 | 0.343 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.703926e-01 | 0.328 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 4.725226e-01 | 0.326 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 4.747866e-01 | 0.324 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 4.769481e-01 | 0.322 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.769481e-01 | 0.322 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 4.769481e-01 | 0.322 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.769481e-01 | 0.322 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 4.769481e-01 | 0.322 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 4.769481e-01 | 0.322 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 4.769481e-01 | 0.322 | 0 | 0 |
| GABA synthesis | R-HSA-888568 | 4.769481e-01 | 0.322 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.769481e-01 | 0.322 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 4.771817e-01 | 0.321 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 4.771817e-01 | 0.321 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 4.796247e-01 | 0.319 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 4.796247e-01 | 0.319 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 4.796247e-01 | 0.319 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 4.796247e-01 | 0.319 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 4.796247e-01 | 0.319 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 4.813868e-01 | 0.318 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 4.813868e-01 | 0.318 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.815610e-01 | 0.317 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 4.815610e-01 | 0.317 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 4.815610e-01 | 0.317 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.815610e-01 | 0.317 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 4.815610e-01 | 0.317 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 4.815610e-01 | 0.317 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 4.815610e-01 | 0.317 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 4.815610e-01 | 0.317 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.815610e-01 | 0.317 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 4.815610e-01 | 0.317 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 4.842314e-01 | 0.315 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 4.842314e-01 | 0.315 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.842314e-01 | 0.315 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 4.873864e-01 | 0.312 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 4.950918e-01 | 0.305 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 4.950918e-01 | 0.305 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 4.950918e-01 | 0.305 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.993874e-01 | 0.302 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.999535e-01 | 0.301 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 4.999535e-01 | 0.301 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 5.000813e-01 | 0.301 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 5.000813e-01 | 0.301 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 5.042179e-01 | 0.297 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 5.064615e-01 | 0.295 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 5.064615e-01 | 0.295 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.154731e-01 | 0.288 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 5.154731e-01 | 0.288 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 5.154731e-01 | 0.288 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 5.154731e-01 | 0.288 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.154731e-01 | 0.288 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 5.154731e-01 | 0.288 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.154731e-01 | 0.288 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 5.154731e-01 | 0.288 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 5.154731e-01 | 0.288 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 5.208620e-01 | 0.283 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 5.225337e-01 | 0.282 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.225337e-01 | 0.282 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 5.225337e-01 | 0.282 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.253040e-01 | 0.280 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 5.254362e-01 | 0.279 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 5.271343e-01 | 0.278 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 5.271343e-01 | 0.278 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.305110e-01 | 0.275 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.305110e-01 | 0.275 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.305110e-01 | 0.275 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.305110e-01 | 0.275 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 5.305110e-01 | 0.275 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.305110e-01 | 0.275 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 5.305110e-01 | 0.275 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.305110e-01 | 0.275 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.305110e-01 | 0.275 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 5.305110e-01 | 0.275 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 5.315157e-01 | 0.274 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 5.325588e-01 | 0.274 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 5.426395e-01 | 0.265 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.444922e-01 | 0.264 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 5.444922e-01 | 0.264 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 5.444922e-01 | 0.264 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 5.444922e-01 | 0.264 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 5.452107e-01 | 0.263 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 5.478795e-01 | 0.261 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.478795e-01 | 0.261 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.478795e-01 | 0.261 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 5.478795e-01 | 0.261 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 5.540558e-01 | 0.256 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.540769e-01 | 0.256 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 5.578586e-01 | 0.253 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 5.578586e-01 | 0.253 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 5.578586e-01 | 0.253 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.611826e-01 | 0.251 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 5.659163e-01 | 0.247 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 5.694460e-01 | 0.245 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 5.729485e-01 | 0.242 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 5.729485e-01 | 0.242 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 5.785917e-01 | 0.238 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 5.785917e-01 | 0.238 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 5.785917e-01 | 0.238 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.785917e-01 | 0.238 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 5.785917e-01 | 0.238 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 5.785917e-01 | 0.238 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 5.785917e-01 | 0.238 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 5.785917e-01 | 0.238 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 5.785917e-01 | 0.238 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 5.785917e-01 | 0.238 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.785917e-01 | 0.238 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 5.785917e-01 | 0.238 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 5.785917e-01 | 0.238 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 5.785917e-01 | 0.238 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 5.785917e-01 | 0.238 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 5.785917e-01 | 0.238 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 5.785917e-01 | 0.238 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 5.785917e-01 | 0.238 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 5.787328e-01 | 0.238 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 5.787328e-01 | 0.238 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 5.787328e-01 | 0.238 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 5.792926e-01 | 0.237 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.792926e-01 | 0.237 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.792926e-01 | 0.237 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 5.804287e-01 | 0.236 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 5.819967e-01 | 0.235 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 5.819967e-01 | 0.235 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 5.823154e-01 | 0.235 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 5.823154e-01 | 0.235 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 5.823154e-01 | 0.235 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 5.823154e-01 | 0.235 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 5.823154e-01 | 0.235 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 5.823154e-01 | 0.235 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.848505e-01 | 0.233 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 5.851250e-01 | 0.233 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.856765e-01 | 0.232 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 5.867719e-01 | 0.232 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 5.960214e-01 | 0.225 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 5.960214e-01 | 0.225 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 5.961184e-01 | 0.225 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 6.005174e-01 | 0.221 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 6.005174e-01 | 0.221 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 6.005174e-01 | 0.221 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 6.005174e-01 | 0.221 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 6.005174e-01 | 0.221 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.048763e-01 | 0.218 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.048763e-01 | 0.218 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 6.048763e-01 | 0.218 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 6.058947e-01 | 0.218 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 6.058947e-01 | 0.218 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 6.058947e-01 | 0.218 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 6.058947e-01 | 0.218 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.058947e-01 | 0.218 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 6.070305e-01 | 0.217 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 6.070305e-01 | 0.217 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 6.070305e-01 | 0.217 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 6.070305e-01 | 0.217 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 6.070305e-01 | 0.217 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 6.080112e-01 | 0.216 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.080112e-01 | 0.216 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 6.080112e-01 | 0.216 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.080112e-01 | 0.216 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.080112e-01 | 0.216 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 6.080112e-01 | 0.216 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 6.080112e-01 | 0.216 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 6.080112e-01 | 0.216 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.094293e-01 | 0.215 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 6.156085e-01 | 0.211 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.176684e-01 | 0.209 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 6.177361e-01 | 0.209 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.217509e-01 | 0.206 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.217509e-01 | 0.206 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.217509e-01 | 0.206 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 6.217509e-01 | 0.206 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.217509e-01 | 0.206 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.217509e-01 | 0.206 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 6.217509e-01 | 0.206 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 6.217509e-01 | 0.206 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 6.217509e-01 | 0.206 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.283812e-01 | 0.202 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 6.285718e-01 | 0.202 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 6.289473e-01 | 0.201 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 6.303850e-01 | 0.200 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 6.327315e-01 | 0.199 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.357138e-01 | 0.197 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 6.357138e-01 | 0.197 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 6.357138e-01 | 0.197 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.357138e-01 | 0.197 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.456709e-01 | 0.190 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 6.462437e-01 | 0.190 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.503309e-01 | 0.187 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 6.503309e-01 | 0.187 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 6.503309e-01 | 0.187 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 6.503309e-01 | 0.187 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 6.503309e-01 | 0.187 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 6.589503e-01 | 0.181 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 6.594669e-01 | 0.181 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 6.604922e-01 | 0.180 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 6.604922e-01 | 0.180 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 6.604922e-01 | 0.180 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 6.604922e-01 | 0.180 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 6.604922e-01 | 0.180 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.604922e-01 | 0.180 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 6.604922e-01 | 0.180 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.604922e-01 | 0.180 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.604922e-01 | 0.180 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.604922e-01 | 0.180 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.604922e-01 | 0.180 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 6.604922e-01 | 0.180 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 6.604922e-01 | 0.180 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 6.618561e-01 | 0.179 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.618561e-01 | 0.179 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 6.618561e-01 | 0.179 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 6.618561e-01 | 0.179 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.618561e-01 | 0.179 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 6.618561e-01 | 0.179 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 6.618561e-01 | 0.179 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 6.618561e-01 | 0.179 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 6.640218e-01 | 0.178 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 6.640218e-01 | 0.178 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 6.640218e-01 | 0.178 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 6.640218e-01 | 0.178 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 6.651746e-01 | 0.177 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 6.711643e-01 | 0.173 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 6.711643e-01 | 0.173 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 6.718188e-01 | 0.173 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 6.727205e-01 | 0.172 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 6.728508e-01 | 0.172 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 6.772737e-01 | 0.169 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 6.817135e-01 | 0.166 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.840176e-01 | 0.165 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 6.847954e-01 | 0.164 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.864672e-01 | 0.163 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.864672e-01 | 0.163 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 6.864672e-01 | 0.163 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 6.864672e-01 | 0.163 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 6.883456e-01 | 0.162 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 6.910709e-01 | 0.160 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 6.910709e-01 | 0.160 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 6.910709e-01 | 0.160 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 6.910709e-01 | 0.160 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 6.910709e-01 | 0.160 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 6.910709e-01 | 0.160 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 6.922032e-01 | 0.160 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 6.922032e-01 | 0.160 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 6.952676e-01 | 0.158 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 6.952676e-01 | 0.158 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.952676e-01 | 0.158 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 6.952676e-01 | 0.158 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 6.952676e-01 | 0.158 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 6.952676e-01 | 0.158 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 6.952676e-01 | 0.158 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.952676e-01 | 0.158 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 6.952676e-01 | 0.158 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 6.952676e-01 | 0.158 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 6.952676e-01 | 0.158 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.952676e-01 | 0.158 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 6.952676e-01 | 0.158 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 6.952676e-01 | 0.158 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 6.952676e-01 | 0.158 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 6.952676e-01 | 0.158 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.987412e-01 | 0.156 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 6.987412e-01 | 0.156 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 7.022939e-01 | 0.153 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.067919e-01 | 0.151 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.072273e-01 | 0.150 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 7.095863e-01 | 0.149 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 7.095863e-01 | 0.149 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 7.095863e-01 | 0.149 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 7.095863e-01 | 0.149 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 7.095863e-01 | 0.149 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 7.100558e-01 | 0.149 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 7.100558e-01 | 0.149 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.100558e-01 | 0.149 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 7.151037e-01 | 0.146 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 7.151037e-01 | 0.146 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 7.151037e-01 | 0.146 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.158148e-01 | 0.145 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 7.264828e-01 | 0.139 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 7.264828e-01 | 0.139 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.264828e-01 | 0.139 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 7.264828e-01 | 0.139 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.264828e-01 | 0.139 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 7.264828e-01 | 0.139 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.264828e-01 | 0.139 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.264828e-01 | 0.139 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.281294e-01 | 0.138 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.281294e-01 | 0.138 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.281294e-01 | 0.138 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 7.281294e-01 | 0.138 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.289060e-01 | 0.137 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 7.308031e-01 | 0.136 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 7.308031e-01 | 0.136 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 7.312609e-01 | 0.136 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 7.312609e-01 | 0.136 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 7.312609e-01 | 0.136 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 7.312609e-01 | 0.136 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 7.312609e-01 | 0.136 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.312609e-01 | 0.136 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 7.312609e-01 | 0.136 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 7.312609e-01 | 0.136 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 7.323920e-01 | 0.135 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 7.357113e-01 | 0.133 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 7.390774e-01 | 0.131 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.453064e-01 | 0.128 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 7.458445e-01 | 0.127 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.515443e-01 | 0.124 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 7.515443e-01 | 0.124 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 7.515443e-01 | 0.124 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 7.515443e-01 | 0.124 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 7.515443e-01 | 0.124 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 7.537974e-01 | 0.123 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 7.545021e-01 | 0.122 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 7.545021e-01 | 0.122 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 7.545021e-01 | 0.122 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 7.545021e-01 | 0.122 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.545021e-01 | 0.122 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 7.545021e-01 | 0.122 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 7.545021e-01 | 0.122 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 7.602351e-01 | 0.119 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 7.616052e-01 | 0.118 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.616052e-01 | 0.118 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.621182e-01 | 0.118 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 7.704939e-01 | 0.113 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 7.704939e-01 | 0.113 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 7.704939e-01 | 0.113 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 7.704939e-01 | 0.113 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 7.704939e-01 | 0.113 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 7.739849e-01 | 0.111 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 7.745525e-01 | 0.111 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 7.750049e-01 | 0.111 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 7.758390e-01 | 0.110 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 7.770474e-01 | 0.110 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.796526e-01 | 0.108 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 7.796526e-01 | 0.108 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 7.796526e-01 | 0.108 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 7.796526e-01 | 0.108 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 7.796526e-01 | 0.108 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.796526e-01 | 0.108 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 7.796526e-01 | 0.108 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.796526e-01 | 0.108 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 7.796526e-01 | 0.108 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 7.796526e-01 | 0.108 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.796526e-01 | 0.108 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 7.879359e-01 | 0.104 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.881701e-01 | 0.103 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.881701e-01 | 0.103 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 7.881701e-01 | 0.103 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 7.881701e-01 | 0.103 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 7.881701e-01 | 0.103 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.916571e-01 | 0.101 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 7.917929e-01 | 0.101 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 7.984779e-01 | 0.098 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 8.022278e-01 | 0.096 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 8.022278e-01 | 0.096 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 8.022278e-01 | 0.096 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 8.022278e-01 | 0.096 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 8.022278e-01 | 0.096 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 8.022278e-01 | 0.096 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 8.022278e-01 | 0.096 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 8.022278e-01 | 0.096 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.022278e-01 | 0.096 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.046349e-01 | 0.094 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 8.046349e-01 | 0.094 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.046349e-01 | 0.094 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 8.054604e-01 | 0.094 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 8.054604e-01 | 0.094 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 8.054604e-01 | 0.094 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.086105e-01 | 0.092 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 8.097916e-01 | 0.092 | 0 | 0 |
| Translation | R-HSA-72766 | 8.112623e-01 | 0.091 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.184852e-01 | 0.087 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 8.184852e-01 | 0.087 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.184852e-01 | 0.087 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.184852e-01 | 0.087 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.184852e-01 | 0.087 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.184852e-01 | 0.087 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.184852e-01 | 0.087 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.184852e-01 | 0.087 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.199510e-01 | 0.086 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 8.199510e-01 | 0.086 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 8.224913e-01 | 0.085 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 8.224913e-01 | 0.085 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 8.224913e-01 | 0.085 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 8.224913e-01 | 0.085 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 8.224913e-01 | 0.085 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 8.224913e-01 | 0.085 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.224913e-01 | 0.085 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.224913e-01 | 0.085 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.224913e-01 | 0.085 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 8.224913e-01 | 0.085 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.224913e-01 | 0.085 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.224913e-01 | 0.085 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 8.224913e-01 | 0.085 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 8.224913e-01 | 0.085 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 8.224913e-01 | 0.085 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 8.228331e-01 | 0.085 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 8.228331e-01 | 0.085 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.228331e-01 | 0.085 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.228331e-01 | 0.085 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 8.228331e-01 | 0.085 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.335839e-01 | 0.079 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 8.341807e-01 | 0.079 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.341807e-01 | 0.079 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 8.341807e-01 | 0.079 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 8.406797e-01 | 0.075 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 8.406797e-01 | 0.075 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.406797e-01 | 0.075 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.406797e-01 | 0.075 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.406797e-01 | 0.075 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.406797e-01 | 0.075 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.406797e-01 | 0.075 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.406797e-01 | 0.075 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 8.406797e-01 | 0.075 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 8.406797e-01 | 0.075 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.423149e-01 | 0.075 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 8.423149e-01 | 0.075 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 8.423149e-01 | 0.075 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 8.437844e-01 | 0.074 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.473859e-01 | 0.072 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 8.473859e-01 | 0.072 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 8.473859e-01 | 0.072 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 8.473859e-01 | 0.072 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.473859e-01 | 0.072 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.473859e-01 | 0.072 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 8.531797e-01 | 0.069 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.531797e-01 | 0.069 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 8.531797e-01 | 0.069 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 8.534529e-01 | 0.069 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.534529e-01 | 0.069 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.566554e-01 | 0.067 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 8.570054e-01 | 0.067 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.570054e-01 | 0.067 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.570054e-01 | 0.067 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.570054e-01 | 0.067 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.570054e-01 | 0.067 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.570054e-01 | 0.067 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.570054e-01 | 0.067 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.570054e-01 | 0.067 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 8.593187e-01 | 0.066 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.596271e-01 | 0.066 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 8.596271e-01 | 0.066 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 8.596271e-01 | 0.066 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 8.596271e-01 | 0.066 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 8.633848e-01 | 0.064 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.649113e-01 | 0.063 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 8.649113e-01 | 0.063 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.709630e-01 | 0.060 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 8.709630e-01 | 0.060 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.709630e-01 | 0.060 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 8.712694e-01 | 0.060 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.716591e-01 | 0.060 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 8.716591e-01 | 0.060 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.716591e-01 | 0.060 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.716591e-01 | 0.060 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 8.716591e-01 | 0.060 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 8.716591e-01 | 0.060 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 8.716591e-01 | 0.060 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.727633e-01 | 0.059 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 8.729606e-01 | 0.059 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 8.729606e-01 | 0.059 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 8.774613e-01 | 0.057 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 8.794555e-01 | 0.056 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 8.794555e-01 | 0.056 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 8.794555e-01 | 0.056 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 8.802248e-01 | 0.055 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 8.814508e-01 | 0.055 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.826976e-01 | 0.054 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 8.848118e-01 | 0.053 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 8.848118e-01 | 0.053 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 8.848118e-01 | 0.053 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 8.848118e-01 | 0.053 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 8.848118e-01 | 0.053 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 8.848118e-01 | 0.053 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 8.848118e-01 | 0.053 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 8.848118e-01 | 0.053 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 8.848118e-01 | 0.053 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 8.848118e-01 | 0.053 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 8.848118e-01 | 0.053 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 8.848118e-01 | 0.053 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 8.848118e-01 | 0.053 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 8.871859e-01 | 0.052 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.871859e-01 | 0.052 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 8.903439e-01 | 0.050 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 8.903439e-01 | 0.050 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 8.903439e-01 | 0.050 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 8.903439e-01 | 0.050 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 8.911450e-01 | 0.050 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 8.911450e-01 | 0.050 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 8.944797e-01 | 0.048 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.944797e-01 | 0.048 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 8.966174e-01 | 0.047 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 8.966174e-01 | 0.047 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.966174e-01 | 0.047 | 0 | 0 |
| Biosynthesis of maresin-like SPMs | R-HSA-9027307 | 8.966174e-01 | 0.047 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.982103e-01 | 0.047 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 8.982103e-01 | 0.047 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 8.992156e-01 | 0.046 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.000982e-01 | 0.046 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.000982e-01 | 0.046 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.012881e-01 | 0.045 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.032490e-01 | 0.044 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 9.055646e-01 | 0.043 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.055646e-01 | 0.043 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 9.055646e-01 | 0.043 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.068954e-01 | 0.042 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.072136e-01 | 0.042 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.072136e-01 | 0.042 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.072136e-01 | 0.042 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.072136e-01 | 0.042 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.072136e-01 | 0.042 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 9.072136e-01 | 0.042 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.083604e-01 | 0.042 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 9.083604e-01 | 0.042 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.083604e-01 | 0.042 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.121548e-01 | 0.040 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.124345e-01 | 0.040 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 9.139296e-01 | 0.039 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 9.159791e-01 | 0.038 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.159791e-01 | 0.038 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 9.159791e-01 | 0.038 | 0 | 0 |
| PKA activation | R-HSA-163615 | 9.167243e-01 | 0.038 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 9.167243e-01 | 0.038 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.167243e-01 | 0.038 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.167243e-01 | 0.038 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.188468e-01 | 0.037 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 9.188468e-01 | 0.037 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 9.188468e-01 | 0.037 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.207087e-01 | 0.036 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.218510e-01 | 0.035 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.229994e-01 | 0.035 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 9.229994e-01 | 0.035 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.248275e-01 | 0.034 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.248275e-01 | 0.034 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 9.248275e-01 | 0.034 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 9.248275e-01 | 0.034 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.248275e-01 | 0.034 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.250857e-01 | 0.034 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 9.252606e-01 | 0.034 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.252606e-01 | 0.034 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.252606e-01 | 0.034 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.252606e-01 | 0.034 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 9.252606e-01 | 0.034 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.252606e-01 | 0.034 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 9.252606e-01 | 0.034 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 9.252606e-01 | 0.034 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.252857e-01 | 0.034 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 9.274978e-01 | 0.033 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.274978e-01 | 0.033 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 9.294639e-01 | 0.032 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.294639e-01 | 0.032 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.301149e-01 | 0.031 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.310251e-01 | 0.031 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.329224e-01 | 0.030 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.329224e-01 | 0.030 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 9.329224e-01 | 0.030 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 9.329224e-01 | 0.030 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 9.329224e-01 | 0.030 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 9.329224e-01 | 0.030 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.329224e-01 | 0.030 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.329224e-01 | 0.030 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.329224e-01 | 0.030 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 9.329224e-01 | 0.030 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.329224e-01 | 0.030 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 9.329224e-01 | 0.030 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 9.354127e-01 | 0.029 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 9.354127e-01 | 0.029 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.377734e-01 | 0.028 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 9.393214e-01 | 0.027 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.393214e-01 | 0.027 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 9.397992e-01 | 0.027 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 9.397992e-01 | 0.027 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 9.397992e-01 | 0.027 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 9.397992e-01 | 0.027 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.397992e-01 | 0.027 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.397992e-01 | 0.027 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.408837e-01 | 0.026 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.408837e-01 | 0.026 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.420874e-01 | 0.026 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.459121e-01 | 0.024 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 9.459121e-01 | 0.024 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.459121e-01 | 0.024 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.459713e-01 | 0.024 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 9.459713e-01 | 0.024 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.459713e-01 | 0.024 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.477121e-01 | 0.023 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.505313e-01 | 0.022 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.512108e-01 | 0.022 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.515109e-01 | 0.022 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 9.515109e-01 | 0.022 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.515109e-01 | 0.022 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.515109e-01 | 0.022 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.530775e-01 | 0.021 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.547723e-01 | 0.020 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.547723e-01 | 0.020 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.564828e-01 | 0.019 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.564828e-01 | 0.019 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 9.564828e-01 | 0.019 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.564828e-01 | 0.019 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.564828e-01 | 0.019 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.564828e-01 | 0.019 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.566064e-01 | 0.019 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.586639e-01 | 0.018 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.586639e-01 | 0.018 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.586639e-01 | 0.018 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.599209e-01 | 0.018 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.605484e-01 | 0.017 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.606984e-01 | 0.017 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.609452e-01 | 0.017 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 9.609452e-01 | 0.017 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.609452e-01 | 0.017 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 9.609452e-01 | 0.017 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.612241e-01 | 0.017 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.622334e-01 | 0.017 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 9.622334e-01 | 0.017 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.632430e-01 | 0.016 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.634953e-01 | 0.016 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.642731e-01 | 0.016 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 9.649503e-01 | 0.015 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 9.649503e-01 | 0.015 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.649503e-01 | 0.015 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 9.649503e-01 | 0.015 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 9.649503e-01 | 0.015 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 9.649503e-01 | 0.015 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.655058e-01 | 0.015 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.674337e-01 | 0.014 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.674337e-01 | 0.014 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 9.685044e-01 | 0.014 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.685044e-01 | 0.014 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.685044e-01 | 0.014 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.685044e-01 | 0.014 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.685044e-01 | 0.014 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.685448e-01 | 0.014 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.685448e-01 | 0.014 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 9.685448e-01 | 0.014 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.685448e-01 | 0.014 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.712510e-01 | 0.013 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.712510e-01 | 0.013 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.712510e-01 | 0.013 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.717709e-01 | 0.012 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.717709e-01 | 0.012 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.717709e-01 | 0.012 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.717709e-01 | 0.012 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.733000e-01 | 0.012 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.737918e-01 | 0.012 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.737918e-01 | 0.012 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.737918e-01 | 0.012 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.737921e-01 | 0.012 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.738870e-01 | 0.011 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.746663e-01 | 0.011 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 9.746663e-01 | 0.011 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.746663e-01 | 0.011 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.754096e-01 | 0.011 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.754096e-01 | 0.011 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.760673e-01 | 0.011 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.768736e-01 | 0.010 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 9.772649e-01 | 0.010 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.791628e-01 | 0.009 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.795970e-01 | 0.009 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.800985e-01 | 0.009 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.816752e-01 | 0.008 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.816752e-01 | 0.008 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.816901e-01 | 0.008 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.816901e-01 | 0.008 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.818790e-01 | 0.008 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.822036e-01 | 0.008 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.828997e-01 | 0.007 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.834676e-01 | 0.007 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.838913e-01 | 0.007 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.842636e-01 | 0.007 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.849374e-01 | 0.007 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.849374e-01 | 0.007 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.852544e-01 | 0.006 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.852544e-01 | 0.006 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.852732e-01 | 0.006 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.862797e-01 | 0.006 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.867673e-01 | 0.006 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.867673e-01 | 0.006 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.874156e-01 | 0.006 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.875515e-01 | 0.005 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.881251e-01 | 0.005 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 9.881251e-01 | 0.005 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.881251e-01 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.893437e-01 | 0.005 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.893437e-01 | 0.005 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.893437e-01 | 0.005 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.902744e-01 | 0.004 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.904373e-01 | 0.004 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.904373e-01 | 0.004 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.908666e-01 | 0.004 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.912494e-01 | 0.004 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.914187e-01 | 0.004 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.919575e-01 | 0.004 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.922994e-01 | 0.003 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 9.922994e-01 | 0.003 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.924778e-01 | 0.003 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.931000e-01 | 0.003 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.937991e-01 | 0.003 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.937991e-01 | 0.003 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.943436e-01 | 0.002 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 9.944356e-01 | 0.002 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.946669e-01 | 0.002 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.946669e-01 | 0.002 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.946669e-01 | 0.002 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.946669e-01 | 0.002 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.947611e-01 | 0.002 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.947611e-01 | 0.002 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.951318e-01 | 0.002 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.951318e-01 | 0.002 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.952328e-01 | 0.002 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.959552e-01 | 0.002 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.959795e-01 | 0.002 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.963500e-01 | 0.002 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.963643e-01 | 0.002 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.963923e-01 | 0.002 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.963923e-01 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.963923e-01 | 0.002 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.964100e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.965962e-01 | 0.001 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.968676e-01 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.978067e-01 | 0.001 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.978361e-01 | 0.001 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.979631e-01 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.979631e-01 | 0.001 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.979946e-01 | 0.001 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.980440e-01 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.981515e-01 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.983104e-01 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.983227e-01 | 0.001 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.984295e-01 | 0.001 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.984688e-01 | 0.001 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.985403e-01 | 0.001 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.985760e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.986489e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.987480e-01 | 0.001 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.987480e-01 | 0.001 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.989048e-01 | 0.000 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.989340e-01 | 0.000 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.990174e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.990664e-01 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.991183e-01 | 0.000 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.991183e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.991536e-01 | 0.000 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.992598e-01 | 0.000 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.992902e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.993379e-01 | 0.000 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.993632e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.994286e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.994379e-01 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.995401e-01 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 9.995873e-01 | 0.000 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.996009e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.997020e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.997020e-01 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.997020e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.997326e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.997544e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.998069e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.998153e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.998263e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.998446e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.998446e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.998812e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.998949e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.998990e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999017e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999348e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.999550e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999620e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999620e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.999694e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999808e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999854e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999872e-01 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.999873e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999873e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999874e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999879e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999908e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999945e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.999984e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999988e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999993e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999998e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999999e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999999e-01 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000e+00 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |